-DOCSTART- -X- -X- O

genetic NN O B-OMIM:215600
mapping NN O I-OMIM:215600
of NN O O
the NN O O
copper NN B-Modifier O
toxicosis NN I-Modifier O
locus NN O O
in NN O O
bedlington NN O O
terriers NN O O
to NN O O
dog NN O O
chromosome NN O O
10, NN O O
in NN O O
a NN O O
region NN O O
syntenic NN O O
to NN O O
human NN O O
chromosome NN O O
region NN O O

abnormal NN O B-MSH:D008107
hepatic NN B-SpecificDisease I-MSH:D008107
copper NN I-SpecificDisease B-MSH:D030342
accumulation NN I-SpecificDisease I-MSH:D030342
is NN O I-MSH:D008107
recognized NN O I-MSH:D008107
as NN O B-MSH:D006527
an NN O I-MSH:D006527
inherited NN B-DiseaseClass B-MSH:D008107
disorder NN I-DiseaseClass I-MSH:D008107
in NN O I-OMIM:215600
man, NN O I-OMIM:215600
mouse, NN O B-OMIM:215600
rat NN O I-OMIM:215600
and NN O B-OMIM:215600
dog. NN O B-MSH:D008107
the NN O I-MSH:D008107
major NN O B-MSH:D006527
cause NN O B-OMIM:215600
of NN O O
hepatic NN B-SpecificDisease O
copper NN I-SpecificDisease O
accumulation NN I-SpecificDisease O
in NN O O
man NN O O
is NN O O
a NN O O
dysfunctional NN O O
atp NN O O
7 NN O O
b NN O O

, NN O B-OMIM:215600
using NN O B-MSH:D006527
fluorescence NN O B-OMIM:215600
in NN O B-OMIM:215600
situ NN O O
hybridization NN O O
(fish). NN O O
c NN O O
04107 NN O O
is NN O O
an NN O O
anonymous NN O O
microsatellite NN O O
marker NN O O
closely NN O O
linked NN O O
to NN O O
CT NN B-SpecificDisease O
. NN O O
however, NN O O
bac NN O O
clones NN O O
containing NN O O
atp NN O O
7 NN O O
b NN O O
and NN O O
c NN O O
04107 NN O O
mapped NN O O
to NN O O
the NN O O
canine NN O O
chromosome NN O O
regions NN O O
cfa NN O O
22 NN O O
q NN O O
11 NN O O
and NN O O
cfa NN O O
10 NN O O
q NN O O
26, NN O O
respectively, NN O O
demonstrating NN O O
that NN O O
WD NN B-SpecificDisease O
cannot NN O O
be NN O O

molecular NN O B-MSH:D011125
analysis NN O B-MSH:D011125
of NN O B-MSH:D011125
the NN O B-MSH:D015179
APC NN B-Modifier O
gene NN O O

background/aims NN O B-MSH:D015179
the NN O B-MSH:D011125
development NN O I-MSH:D011125
of NN O I-MSH:D011125
colorectal NN B-SpecificDisease B-MSH:D011125
cancer NN I-SpecificDisease I-MSH:D011125
and NN O B-MSH:D011125
a NN O B-MSH:D011125
variable NN O B-MSH:D011125
range NN O B-MSH:D015179
of NN O I-MSH:D015179
extracolonic NN O B-MSH:D011125
manifestations NN O B-MSH:D011125
in NN O B-MSH:D015179
familial NN B-SpecificDisease B-MSH:D011125
adenomatous NN I-SpecificDisease O
polyposis NN I-SpecificDisease O
( NN O O
FAP NN B-SpecificDisease O
) NN O O
is NN O O
the NN O O
result NN O O
of NN O O
the NN O O
dominant NN O O
inheritance NN O O
of NN O O

whom NN O B-MSH:D015179
belonged NN O I-MSH:D015179
to NN O B-MSH:D011125
the NN O B-MSH:D011125
non-fap NN O B-MSH:D015179
group NN O I-MSH:D015179
of NN O O
colorectal NN B-Modifier O

a NN O B-OMIM:261600
european NN O I-OMIM:261600
multicenter NN O I-OMIM:261600
study NN O O
of NN O O
phenylalanine NN B-SpecificDisease O
hydroxylase NN I-SpecificDisease O
deficiency NN I-SpecificDisease O
: NN O O
classification NN O O
of NN O O
105 NN O O
mutations NN O O
and NN O O
a NN O O
general NN O O
system NN O O
for NN O O

phenylketonuria NN O B-MSH:D010661
( NN O B-MSH:D010661
PKU NN B-SpecificDisease I-MSH:D010661
) NN O B-MSH:D010661
and NN O B-MSH:D030342
mild NN B-SpecificDisease B-OMIM:261600
hyperphenylalaninemia NN I-SpecificDisease I-OMIM:261600
( NN O O
MHP NN B-SpecificDisease O
) NN O O
are NN O O
allelic NN B-DiseaseClass O
disorders NN I-DiseaseClass O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
gene NN O O
encoding NN O O
phenylalanine NN O O
hydroxylase NN O O
(pah). NN O O
previous NN O O
studies NN O O
have NN O O
suggested NN O O
that NN O O
the NN O O
highly NN O O
variable NN O O
metabolic NN O O
phenotypes NN O O
of NN O O
PAH NN B-SpecificDisease O
deficiency NN I-SpecificDisease O
correlate NN O O
with NN O O
pah NN O O
genotypes. NN O O
we NN O O
identified NN O O
both NN O O
causative NN O O
mutations NN O O
in NN O O
686 NN O O
patients NN O O
from NN O O
seven NN O O
european NN O O
centers. NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
phenotypic NN O O
characteristics NN O O
of NN O O
297 NN O O
functionally NN O O
hemizygous NN O O
patients, NN O O
105 NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
assigned NN O O
to NN O O
one NN O O
of NN O O
four NN O O
arbitrary NN O O
phenotype NN O O
categories. NN O O
we NN O O
proposed NN O O
and NN O O
tested NN O O
a NN O O
simple NN O O
model NN O O
for NN O O
correlation NN O O
between NN O O
genotype NN O O
and NN O O
phenotypic NN O O
outcome. NN O O
the NN O O
observed NN O O
phenotype NN O O
matched NN O O
the NN O O

proportion NN O B-OMIM:261600
of NN O I-OMIM:261600
patients NN O B-MSH:D010661
for NN O O
whom NN O O
the NN O O
observed NN O O

disruption NN O B-MSH:D009223
of NN O I-MSH:D009223
splicing NN O O
regulated NN O O

myotonic NN O B-MSH:D009223
dystrophy NN O B-MSH:D009223
( NN O B-MSH:D009223
DM NN B-SpecificDisease B-MSH:D009223
) NN O O
is NN O O
caused NN O O
by NN O O
a NN O O
ctg NN O O
expansion NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
the NN O O
DM NN B-Modifier O
gene. NN O O
one NN O O
model NN O O
of NN O O

therefore NN O B-MSH:D009223
may NN O O
contribute NN O O
to NN O O

maternal NN O B-MSH:D011218
disomy NN O I-MSH:D011218
and NN O O
Prader-Willi NN B-SpecificDisease O
syndrome NN I-SpecificDisease O
consistent NN O O
with NN O O
gamete NN O O
complementation NN O O
in NN O O
a NN O O
case NN O O
of NN O O
familial NN O O
translocation NN O O
(3;15) NN O O

maternal NN O B-MSH:D011218
uniparental NN O I-MSH:D011218
disomy NN O B-MSH:D011218
(upd) NN O B-MSH:C538037
for NN O I-MSH:C538037
chromosome NN O I-MSH:C538037
15 NN O B-MSH:D011218
is NN O B-MSH:D011218
responsible NN O O
for NN O O
an NN O O
estimated NN O O
30% NN O O
of NN O O
cases NN O O
of NN O O
Prader-Willi NN B-SpecificDisease O
syndrome NN I-SpecificDisease O
( NN O O
PWS NN B-SpecificDisease O
). NN O O
we NN O O
report NN O O
on NN O O
an NN O O
unusual NN O O
case NN O O
of NN O O
maternal NN B-SpecificDisease O
disomy NN I-SpecificDisease O
15 NN I-SpecificDisease O
in NN O O
PWS NN B-SpecificDisease O
that NN O O
is NN O O
most NN O O
consistent NN O O
with NN O O
adjacent-1 NN O O
segregation NN O O
of NN O O

in NN O B-MSH:D011218
the NN O B-MSH:D011218
balanced NN O B-MSH:D024182
state NN O I-MSH:D024182
in NN O O
the NN O O
patients NN O O
father NN O O
and NN O O
a NN O O
sister. NN O O
fluorescent NN O O
in NN O O
situ NN O O
hybridization NN O O
analysis NN O O
demonstrated NN O O
that NN O O
the NN O O
PWS NN B-Modifier O
critical NN O O
region NN O O
resided NN O O
on NN O O
the NN O O
derivative NN O O
chromosome NN O O
3 NN O O
and NN O O
that NN O O
there NN O O
was NN O O
no NN O O
deletion NN O O
of NN O O
the NN O O
PWS NN B-Modifier O
region NN O O
on NN O O
the NN O O
normal NN O O
pair NN O O
of NN O O
15 NN O O

that NN O B-MSH:D024182
reported NN O I-MSH:D024182
for NN O B-MSH:D011218
haploinsufficiency NN O B-MSH:C538037
of NN O I-MSH:C538037
distal NN O I-MSH:C538037
3 NN O B-MSH:D011218
p. NN O O

segregation NN O B-MSH:D009223
distortion NN O I-MSH:D009223
in NN O O

myotonic NN O B-MSH:D009223
dystrophy NN O B-MSH:D030342
( NN O I-MSH:D030342
DM NN B-SpecificDisease I-MSH:D030342
) NN O B-MSH:D007246
is NN O B-MSH:D009223
an NN O I-MSH:D009223
autosomal NN B-DiseaseClass B-MSH:D009223
dominant NN I-DiseaseClass B-MSH:D009223
disease NN I-DiseaseClass B-MSH:D009223
which, NN O B-MSH:D009223
in NN O B-MSH:D009223
the NN O O
typical NN O O
pedigree, NN O O
shows NN O O
a NN O O
three NN O O
generation NN O O
anticipation NN O O
cascade. NN O O
this NN O O
results NN O O
in NN O O
infertility NN B-SpecificDisease O
and NN O O
congenital NN B-SpecificDisease O
myotonic NN I-SpecificDisease O
dystrophy NN I-SpecificDisease O
( NN O O
CDM NN B-SpecificDisease O
) NN O O

the NN O B-MSH:D009223
case NN O B-MSH:D009223
of NN O B-MSH:D009223
a NN O O
female NN O O
transmitting NN O O
parent, NN O O
68. NN O O
7% NN O O
were NN O O
affected. NN O O

ataxia-telangiectasia: NN O O

to NN O B-MSH:D001943
facilitate NN O I-MSH:D001943
the NN O B-MSH:D001260
evaluation NN O B-MSH:D001260
of NN O O
atm NN O O
heterozygotes NN O O
for NN O O
susceptibility NN O O
to NN O O
other NN O O
diseases, NN O O
such NN O O
as NN O O
breast NN B-SpecificDisease O
cancer NN I-SpecificDisease O
, NN O O
we NN O O
have NN O O
attempted NN O O
to NN O O
define NN O O
the NN O O
most NN O O
common NN O O
mutations NN O O
and NN O O
their NN O O
frequencies NN O O
in NN O O
ataxia-telangiectasia NN B-Modifier O
( NN O O
A-T NN B-Modifier O
) NN O O
homozygotes NN O O
from NN O O
10 NN O O
ethnic NN O O
populations. NN O O
both NN O O
genomic NN O O
mutations NN O O
and NN O O
their NN O O
effects NN O O
on NN O O
cdna NN O O
were NN O O
characterized. NN O O
protein-truncation NN O O
testing NN O O
of NN O O
the NN O O
entire NN O O
atm NN O O
cdna NN O O
detected NN O O
92 NN O O
(66%) NN O O
truncating NN O O
mutations NN O O
in NN O O
140 NN O O
mutant NN O O
alleles NN O O
screened. NN O O
the NN O O
haplotyping NN O O
of NN O O
patients NN O O
with NN O O
identical NN O O
mutations NN O O
indicates NN O O
that NN O O
almost NN O O
all NN O O
of NN O O
these NN O O
represent NN O O
common NN O O
ancestry NN O O
and NN O O
that NN O O
very NN O O
few NN O O
spontaneously NN O O
recurring NN O O
atm NN O O
mutations NN O O

% NN O B-MSH:D001260
of NN O O
norwegian NN O O
patients NN O O
(1), NN O O
25% NN O O
of NN O O
polish NN O O

constitutional NN O B-MSH:D012175
rb NN O I-MSH:D012175
1-gene NN O O
mutations NN O O

in NN O B-MSH:D012175
most NN O I-MSH:D012175
patients NN O B-MSH:D009369
with NN O B-MSH:D012175
isolated NN O B-MSH:D012175
unilateral NN B-SpecificDisease B-MSH:D009369
retinoblastoma NN I-SpecificDisease B-MSH:D009369
, NN O B-MSH:D009369
tumor NN B-Modifier O
development NN O O
is NN O O
initiated NN O O
by NN O O
somatic NN O O
inactivation NN O O
of NN O O
both NN O O
alleles NN O O
of NN O O
the NN O O
rb NN O O
1 NN O O
gene. NN O O
however, NN O O
some NN O O
of NN O O
these NN O O
patients NN O O
can NN O O

tumors NN O B-MSH:D009369
with NN O B-MSH:D009369
loh. NN O B-MSH:D009369
in NN O O
6 NN O O
(38%) NN O O
of NN O O
16 NN O O
tumors NN B-DiseaseClass O
without NN O O
loh, NN O O
one NN O O
mutation NN O O
was NN O O
detected, NN O O
and NN O O
in NN O O
9 NN O O
(56%) NN O O
of NN O O
the NN O O
tumors NN B-DiseaseClass O
without NN O O
loh, NN O O
both NN O O
mutations NN O O
were NN O O
found. NN O O
thus, NN O O
a NN O O
total NN O O
of NN O O
45 NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
tumors NN B-DiseaseClass O
of NN O O
36 NN O O
patients. NN O O
thirty-nine NN O O
of NN O O
the NN O O
mutations-including NN O O
34 NN O O
small NN O O
mutations, NN O O
2 NN O O
large NN O O
structural NN O O
alterations, NN O O
and NN O O
hypermethylation NN O O
in NN O O
3 NN O O
tumors-were NN O O
not NN O O
detected NN O O
in NN O O
the NN O O
corresponding NN O O
peripheral NN O O
blood NN O O
dna. NN O O
in NN O O
6 NN O O
(17%) NN O O
of NN O O
the NN O O
36 NN O O

somatic NN O B-MSH:D009369
mosaicism NN O B-MSH:D012175
was NN O I-MSH:D012175
demonstrated NN O B-MSH:D012175
by NN O O
molecular NN O O
analysis NN O O
of NN O O
dna NN O O
and NN O O
rna NN O O
from NN O O
peripheral NN O O
blood. NN O O
in NN O O
2 NN O O
patients NN O O
without NN O O
a NN O O
detectable NN O O
mutation NN O O
in NN O O
peripheral NN O O
blood, NN O O
mosaicism NN O O
was NN O O
suggested NN O O
because NN O O

missense NN O B-MSH:D005124
mutations NN O I-MSH:D005124
in NN O I-MSH:D005124
the NN O O
most NN O O

mutations NN O B-MSH:D015783
of NN O B-MSH:D015783
the NN O I-MSH:D015783
human NN O I-MSH:D015783
pax NN O I-MSH:D015783
6 NN O I-MSH:D015783
gene NN O B-MSH:D005124
underlie NN O I-MSH:D005124
aniridia NN B-SpecificDisease I-MSH:D005124
( NN O B-MSH:D015783
congenital NN B-SpecificDisease O
absence NN I-SpecificDisease O
of NN I-SpecificDisease O
the NN I-SpecificDisease O
iris NN I-SpecificDisease O
), NN O O
a NN O O
rare NN O O
dominant NN O O
malformation NN B-DiseaseClass O
of NN I-DiseaseClass O
the NN I-DiseaseClass O
eye NN I-DiseaseClass O
. NN O O
the NN O O
spectrum NN O O
of NN O O
pax NN O O
6 NN O O
mutations NN O O
in NN O O
aniridia NN B-Modifier O
patients NN O O
is NN O O
highly NN O O
biased, NN O O

mutations NN O B-MSH:D015783
frequently NN O B-MSH:C536185
may NN O I-MSH:C536185
underlie NN O B-MSH:C536185
phenotypes NN O I-MSH:C536185
distinct NN O B-MSH:D020417
from NN O I-MSH:D020417
textbook NN O B-MSH:D020417
aniridia NN B-SpecificDisease B-MSH:D015783
. NN O B-OMIM:106210
here NN O I-OMIM:106210
we NN O I-OMIM:106210
present NN O O
four NN O O
novel NN O O
pax NN O O
6 NN O O
missense NN O O

somatic NN O B-MSH:D009223
instability NN O I-MSH:D009223
of NN O O
the NN O O
ctg NN O O
repeat NN O O
in NN O O
mice NN O O
transgenic NN O O
for NN O O
the NN O O
myotonic NN B-Modifier O
dystrophy NN I-Modifier O
region NN O O
is NN O O
age NN O O
dependent NN O O
but NN O O

a NN O B-MSH:D009223
(ctg) NN O I-MSH:D009223
nexpansion NN O B-MSH:D009223
in NN O B-MSH:D009223
the NN O B-MSH:D030342
3-untranslated NN O I-MSH:D030342
region NN O B-MSH:D009223
(utr) NN O O
of NN O O
the NN O O
dm NN O O
protein NN O O
kinase NN O O
gene NN O O
(dmpk) NN O O
is NN O O
responsible NN O O
for NN O O
causing NN O O

reproduce NN O B-MSH:D009223
the NN O O
intergenerational NN O O
and NN O O
somatic NN O O
instability NN O O
of NN O O
the NN O O
55 NN O O
ctg NN O O
repeat NN O O
suggesting NN O O
that NN O O
surrounding NN O O
sequences NN O O
and NN O O
the NN O O
chromatin NN O O
environment NN O O
are NN O O
involved NN O O
in NN O O
instability NN O O
mechanisms. NN O O
as NN O O
observed NN O O
in NN O O
some NN O O
of NN O O
the NN O O
tissues NN O O
of NN O O
DM NN B-Modifier O
patients, NN O O
there NN O O
is NN O O
a NN O O
tendency NN O O
for NN O O
repeat NN O O
length NN O O
and NN O O
somatic NN O O
mosaicism NN O O
to NN O O
increase NN O O
with NN O O
the NN O O
age NN O O
of NN O O
the NN O O
mouse. NN O O
furthermore, NN O O
we NN O O
observed NN O O
no NN O O
correlation NN O O
between NN O O
the NN O O
somatic NN O O
mutation NN O O
rate NN O O
and NN O O
tissue NN O O

atm NN O B-MSH:D001260
mutations NN O B-MSH:D007938
and NN O B-MSH:D008223
phenotypes NN O B-MSH:D001943
in NN O I-MSH:D001943
ataxia-telangiectasia NN B-Modifier O

we NN O B-MSH:D001260
report NN O B-MSH:D001260
the NN O B-MSH:D013132
spectrum NN O I-MSH:D013132
of NN O B-MSH:D001260
59 NN O B-MSH:D001943
atm NN O I-MSH:D001943
mutations NN O B-MSH:D001260
observed NN O B-MSH:D013132
in NN O I-MSH:D013132
ataxia-telangiectasia NN B-Modifier O
( NN O O
A-T NN B-Modifier O
) NN O O
patients NN O O
in NN O O

) NN O B-MSH:D001260
also NN O B-MSH:D007938
allows NN O B-MSH:D008223
expression NN O B-MSH:D006689
of NN O I-MSH:D006689
full-length NN O B-MSH:D001260
atm NN O O
protein NN O O
at NN O O
a NN O O
level NN O O
comparable NN O O
with NN O O
that NN O O
in NN O O
unaffected NN O O
individuals. NN O O
in NN O O
addition, NN O O
we NN O O
have NN O O
studied NN O O
18 NN O O
A-T NN B-Modifier O
patients, NN O O

low NN O B-MSH:D061325
frequency NN O I-MSH:D061325
of NN O O
brca NN O O
1 NN O O

in NN O B-MSH:D061325
this NN O I-MSH:D061325
study NN O B-MSH:D001943
we NN O I-MSH:D001943
investigated NN O B-MSH:D061325
45 NN O I-MSH:D061325
german NN O O
breast/ovarian NN B-Modifier O
cancer NN I-Modifier O
families NN O O
for NN O O
germline NN O O
mutations NN O O
in NN O O
the NN O O
brca NN O O
1 NN O O
gene. NN O O
we NN O O
identified NN O O
four NN O O
germline NN O O
mutations NN O O
in NN O O
three NN O O
breast NN B-Modifier O
cancer NN I-Modifier O
families NN O O
and NN O O
in NN O O
one NN O O
breast-ovarian NN B-Modifier O
cancer NN I-Modifier O
family. NN O O
among NN O O
these NN O O
were NN O O
one NN O O
frameshift NN O O
mutation, NN O O
one NN O O
nonsense NN O O
mutation, NN O O
one NN O O
novel NN O O
splice NN O O
site NN O O
mutation, NN O O
and NN O O
one NN O O
missense NN O O
mutation. NN O O
the NN O O
missense NN O O
mutation NN O O
was NN O O
also NN O O
found NN O O
in NN O O
2. NN O O
8% NN O O
of NN O O
the NN O O
general NN O O
population, NN O O
suggesting NN O O
that NN O O
it NN O O
is NN O O
not NN O O
disease NN O O
associated. NN O O
the NN O O
average NN O O
age NN O O
of NN O O
disease NN O O
onset NN O O
in NN O O
those NN O O
families NN O O
harbouring NN O O
causative NN O O
mutations NN O O
was NN O O
between NN O O
32. NN O O
3 NN O O
and NN O O
37. NN O O

of NN O B-MSH:D061325
breast/ovarian NN B-Modifier O
cancer NN I-Modifier O
families NN O O
suggesting NN O O
the NN O O
involvement NN O O
of NN O O
another NN O O
susceptibility NN O O
gene NN O O

oral NN O B-MSH:D061325
contraceptives NN O I-MSH:D061325
and NN O I-MSH:D061325
the NN O B-MSH:D061325
risk NN O I-MSH:D061325
of NN O I-MSH:D061325
hereditary NN B-SpecificDisease O
ovarian NN I-SpecificDisease O
cancer NN I-SpecificDisease O
. NN O O

background NN O B-MSH:D010051
women NN O B-MSH:D010051
with NN O I-MSH:D010051
mutations NN O B-MSH:D061325
in NN O I-MSH:D061325
either NN O I-MSH:D061325
the NN O I-MSH:D061325
brca NN O I-MSH:D061325
1 NN O B-MSH:D061325
or NN O I-MSH:D061325
the NN O I-MSH:D061325
brca NN O O
2 NN O O
gene NN O O
have NN O O
a NN O O
high NN O O
lifetime NN O O
risk NN O O
of NN O O
ovarian NN B-SpecificDisease O
cancer NN I-SpecificDisease O
. NN O O
oral NN O O
contraceptives NN O O
protect NN O O
against NN O O
ovarian NN B-SpecificDisease O
cancer NN I-SpecificDisease O
in NN O O
general, NN O O
but NN O O
it NN O O
is NN O O
not NN O O
known NN O O
whether NN O O
they NN O O
also NN O O
protect NN O O
against NN O O
hereditary NN B-SpecificDisease O
forms NN I-SpecificDisease O
of NN I-SpecificDisease O
ovarian NN I-SpecificDisease O
cancer NN I-SpecificDisease O
. NN O O
methods NN O O
we NN O O
enrolled NN O O
207 NN O O
women NN O O
with NN O O
hereditary NN B-SpecificDisease O
ovarian NN I-SpecificDisease O
cancer NN I-SpecificDisease O
and NN O O
161 NN O O
of NN O O
their NN O O
sisters NN O O
as NN O O
controls NN O O
in NN O O
a NN O O
case-control NN O O
study. NN O O
all NN O O
the NN O O
patients NN O O
carried NN O O
a NN O O
pathogenic NN O O
mutation NN O O
in NN O O
either NN O O
brca NN O O

parity. NN O B-MSH:D010051
results NN O I-MSH:D010051
the NN O I-MSH:D010051
adjusted NN O O
odds NN O O
ratio NN O O
for NN O O
ovarian NN B-SpecificDisease O
cancer NN I-SpecificDisease O
associated NN O O
with NN O O
any NN O O
past NN O O
use NN O O
of NN O O
oral NN O O
contraceptives NN O O
was NN O O
0. NN O O
5 NN O O
(95 NN O O
percent NN O O
confidence NN O O
interval, NN O O
0. NN O O
3 NN O O
to NN O O
0. NN O O
8). NN O O
the NN O O
risk NN O O
decreased NN O O
with NN O O
increasing NN O O
duration NN O O
of NN O O
use NN O O
(p NN O O
for NN O O
trend, NN O O
< NN O O
0. NN O O
001); NN O O
use NN O O
for NN O O
six NN O O

oral-contraceptive NN O B-MSH:D010051
use NN O I-MSH:D010051
may NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
ovarian NN B-SpecificDisease O
cancer NN I-SpecificDisease O
in NN O O
women NN O O
with NN O O
pathogenic NN O O
mutations NN O O
in NN O O

founder NN O B-MSH:D061325
brca NN O I-MSH:D061325
1 NN O I-MSH:D061325
and NN O I-MSH:D061325
brca NN O O
2 NN O O
mutations NN O O

we NN O B-MSH:D001943
have NN O I-MSH:D001943
identified NN O B-MSH:D001943
four NN O I-MSH:D001943
mutations NN O B-MSH:D061325
in NN O I-MSH:D061325
each NN O B-MSH:D009369
of NN O B-MSH:D010051
the NN O I-MSH:D010051

cancer NN O B-MSH:D001943
were NN O I-MSH:D001943
also NN O B-MSH:D001943
present NN O I-MSH:D001943
in NN O B-MSH:D001943
the NN O I-MSH:D001943
family. NN O B-MSH:D061325
the NN O I-MSH:D061325
odds NN O O
of NN O O
detection NN O O

truncation NN O O

pax NN O B-MSH:D015783
6 NN O B-MSH:C537884
is NN O I-MSH:C537884
a NN O B-MSH:C537022
transcription NN O I-MSH:C537022
factor NN O I-MSH:C537022
with NN O B-OMIM:136520
two NN O I-OMIM:136520
dna-binding NN O I-OMIM:136520
domains NN O B-MSH:D015783
(paired NN O B-MSH:D015783
box NN O O
and NN O O
homeobox) NN O O
and NN O O
a NN O O
proline-serine-threonine NN O O
(pst) NN O O
-rich NN O O
transactivation NN O O
domain. NN O O
pax NN O O
6 NN O O
regulates NN O O
eye NN O O
development NN O O
in NN O O
animals NN O O
ranging NN O O

domain. NN O B-MSH:D015783
it NN O O
is NN O O

crystal NN O B-MSH:D006432
structure NN O O
of NN O O
the NN O O
hemochromatosis NN B-Modifier O
protein NN O O
hfe NN O O
and NN O O
characterization NN O O
of NN O O
its NN O O

hfe NN O B-MSH:D019190
is NN O I-MSH:D019190
an NN O B-MSH:D006432
mhc-related NN O I-MSH:D006432
protein NN O B-MSH:D006432
that NN O O
is NN O O
mutated NN O O
in NN O O
the NN O O
iron-overload NN B-SpecificDisease O
disease NN I-SpecificDisease O
hereditary NN B-SpecificDisease O
hemochromatosis NN I-SpecificDisease O
. NN O O
hfe NN O O
binds NN O O
to NN O O
transferrin NN O O
receptor NN O O
(tfr) NN O O
and NN O O
reduces NN O O
its NN O O
affinity NN O O
for NN O O
iron-loaded NN O O
transferrin, NN O O
implicating NN O O
hfe NN O O
in NN O O
iron NN O O
metabolism. NN O O
the NN O O
2. NN O O
6 NN O O
a NN O O
crystal NN O O
structure NN O O
of NN O O
hfe NN O O
reveals NN O O
the NN O O
locations NN O O
of NN O O
hemochromatosis NN B-Modifier O
mutations NN O O
and NN O O
a NN O O
patch NN O O
of NN O O
histidines NN O O
that NN O O
could NN O O
be NN O O
involved NN O O
in NN O O
ph-dependent NN O O
interactions. NN O O
we NN O O
also NN O O
demonstrate NN O O
that NN O O
soluble NN O O
tfr NN O O
and NN O O
hfe NN O O
bind NN O O
tightly NN O O
at NN O O
the NN O O
basic NN O O
ph NN O O
of NN O O
the NN O O
cell NN O O
surface, NN O O

, NN O O

stable NN O B-MSH:D009369
interaction NN O O
between NN O O
the NN O O
products NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
and NN O O

brca NN O B-MSH:D061325
1 NN O I-MSH:D061325
and NN O I-MSH:D061325
brca NN O I-MSH:D061325
2 NN O B-MSH:D061325
account NN O I-MSH:D061325
for NN O I-MSH:D061325
most NN O I-MSH:D061325
cases NN O I-MSH:D061325
of NN O O

and/or NN O O

a NN O O

a NN O B-MSH:D019294
novel NN O I-MSH:D019294
c NN O B-MSH:D019294
to NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
sterol NN O O
27-hydroxylase NN O O
gene NN O O
(cyp NN O O
27) NN O O
was NN O O
identified NN O O
by NN O O
sequencing NN O O
amplified NN O O
cyp NN O O
27 NN O O
gene NN O O
products NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
cerebrotendinous NN B-SpecificDisease O
xanthomatosis NN I-SpecificDisease O
( NN O O
CTX NN B-SpecificDisease O
). NN O O
the NN O O
mutation NN O O
changed NN O O
the NN O O
adrenodoxin NN O O
cofactor NN O O
binding NN O O
residue NN O O
362 NN O O
arg NN O O
to NN O O
362 NN O O
ser NN O O
(cgt NN O O
362 NN O O
arg NN O O
to NN O O
agt NN O O
362 NN O O
ser), NN O O
and NN O O
was NN O O
responsible NN O O
for NN O O
deficiency NN O O
in NN O O
the NN O O
sterol NN O O
27-hydroxylase NN O O
activity, NN O O
as NN O O
confirmed NN O O
by NN O O
expression NN O O
of NN O O
mutant NN O O
cdna NN O O
into NN O O
cos-1 NN O O
cells. NN O O
quantitative NN O O
analysis NN O O
showed NN O O
that NN O O
the NN O O
expression NN O O
of NN O O
cyp NN O O
27 NN O O
gene NN O O
mrna NN O O
in NN O O
the NN O O
patient NN O O
represented NN O O
52. NN O O
5% NN O O
of NN O O

the NN O B-MSH:D019294
mutation NN O I-MSH:D019294
may NN O I-MSH:D019294
partially NN O I-MSH:D019294
affect NN O I-MSH:D019294
the NN O I-MSH:D019294
normal NN O O
splicing NN O O
efficiency NN O O
in NN O O
exon NN O O
6 NN O O
and NN O O
cause NN O O
alternative NN O O
splicing NN O O
elsewhere, NN O O
which NN O O
resulted NN O O
in NN O O
decreased NN O O
transcript NN O O
in NN O O
the NN O O
patient. NN O O
transfection NN O O
of NN O O
constructed NN O O
minigenes, NN O O
with NN O O
or NN O O
without NN O O
the NN O O
mutation, NN O O

mutation NN O O

a NN O B-MSH:D000326
japanese NN O O
family NN O O
with NN O O
adrenoleukodystrophy NN B-SpecificDisease O
with NN O O
a NN O O
codon NN O O
291 NN O O
deletion: NN O O
a NN O O
clinical, NN O O
biochemical, NN O O

we NN O B-MSH:D000326
report NN O B-MSH:D000326
a NN O B-MSH:D000326
japanese NN O B-MSH:D000326
family NN O B-MSH:D000544
with NN O I-MSH:D000544
adrenoleukodystrophy NN B-SpecificDisease B-MSH:D002526
( NN O I-MSH:D002526
ALD NN B-SpecificDisease I-MSH:D002526
) NN O I-MSH:D002526
with NN O I-MSH:D002526
a NN O O
three NN O O
base NN O O
pair NN O O

stem, NN O B-MSH:D003711
but NN O I-MSH:D003711
not NN O I-MSH:D003711
in NN O I-MSH:D003711
the NN O I-MSH:D003711
cerebral NN O I-MSH:D003711
white NN O B-MSH:D000326
matter, NN O B-MSH:D000326
where NN O B-MSH:D004194
marked NN O I-MSH:D004194
reductions NN O O
of NN O O
the NN O O
cerebral NN O O
blood NN O O
flow NN O O
and NN O O
oxygen NN O O
metabolism NN O O

or NN O B-MSH:D009410
mri NN O I-MSH:D009410
analysis, NN O B-MSH:D000326
and NN O O
that NN O O
the NN O O
higher NN O O
level NN O O
of NN O O
tau NN O O
reflects NN O O
the NN O O
process NN O O
of NN O O

two NN O B-MSH:C536648
frequent NN O I-MSH:C536648
missense NN O O
mutations NN O O

pendred NN O B-MSH:D030342
syndrome NN O I-MSH:D030342
is NN O I-MSH:D030342
an NN O B-MSH:D003638
autosomal NN B-DiseaseClass B-MSH:C536648
recessive NN I-DiseaseClass B-MSH:C536648
disorder NN I-DiseaseClass O
characterized NN O O
by NN O O
early NN O O
childhood NN O O
deafness NN B-SpecificDisease O
and NN O O
goiter NN B-SpecificDisease O
. NN O O
a NN O O
century NN O O
after NN O O
its NN O O
recognition NN O O
as NN O O
a NN O O
syndrome NN O O
by NN O O
vaughan NN O O
pendred, NN O O
the NN O O
disease NN O O
gene NN O O
(pds) NN O O
was NN O O
mapped NN O O
to NN O O
chromosome NN O O
7 NN O O
q NN O O
22-q NN O O
31. NN O O
1 NN O O
and, NN O O
recently, NN O O
found NN O O
to NN O O
encode NN O O
a NN O O
putative NN O O
sulfate NN O O
transporter. NN O O
we NN O O
performed NN O O
mutation NN O O
analysis NN O O
of NN O O
the NN O O
PDS NN B-Modifier O
gene NN O O
in NN O O
patients NN O O
from NN O O
14 NN O O
Pendred NN B-Modifier O

homozygous NN O B-MSH:C536648
state NN O B-MSH:C536648
in NN O B-MSH:C536648
one NN O I-MSH:C536648
family NN O O
and NN O O

aspartylglucosaminuria NN O O

aspartylglucosaminuria NN O B-MSH:D054880
( NN O B-MSH:D008661
AGU NN B-SpecificDisease I-MSH:D008661
) NN O I-MSH:D008661
is NN O I-MSH:D008661
a NN O B-MSH:D054880
rare NN O I-MSH:D054880
disorder NN B-DiseaseClass I-MSH:D054880
of NN I-DiseaseClass I-MSH:D054880
glycoprotein NN I-DiseaseClass I-MSH:D054880
metabolism NN I-DiseaseClass B-MSH:D054880
caused NN O B-MSH:D054880
by NN O O
the NN O O
deficiency NN B-SpecificDisease O
of NN I-SpecificDisease O
the NN I-SpecificDisease O
lysosomal NN I-SpecificDisease O
enzyme NN I-SpecificDisease O
aspartylglucosaminidase NN I-SpecificDisease O
(aga). NN O O
AGU NN B-SpecificDisease O
is NN O O
inherited NN O O
as NN O O
an NN O O
autosomal NN O O
recessive NN O O
trait NN O O
and NN O O
occurs NN O O
with NN O O
a NN O O
high NN O O
frequency NN O O
in NN O O
finland NN O O
because NN O O
of NN O O
a NN O O
founder NN O O
effect. NN O O
while NN O O
very NN O O
few NN O O
patients NN O O
with NN O O
AGU NN B-SpecificDisease O
have NN O O
been NN O O
reported NN O O
from NN O O

mutation NN O B-MSH:D006223
spectrum NN O I-MSH:D006223
and NN O B-MSH:D006223
genotype-phenotype NN O I-MSH:D006223
analyses NN O B-MSH:D006223
in NN O I-MSH:D006223
Cowden NN B-SpecificDisease O
disease NN I-SpecificDisease O
and NN O O

the NN O B-MSH:D009369
tumour NN B-Modifier B-MSH:D001943
suppressor NN O I-MSH:D001943
gene NN O I-MSH:D001943
pten, NN O I-MSH:D001943
which NN O I-MSH:D001943
maps NN O I-MSH:D001943
to NN O B-MSH:D009369
10 NN O B-MSH:D016889
q NN O I-MSH:D016889
23. NN O B-MSH:D008545
3 NN O I-MSH:D008545
and NN O B-MSH:D013964
encodes NN O I-MSH:D013964
a NN O B-MSH:D006223
403 NN O I-MSH:D006223
amino NN O B-MSH:D006223
acid NN O I-MSH:D006223
dual NN O B-MSH:D006223
specificity NN O B-MSH:D006223
phosphatase NN O I-MSH:D006223
(protein NN O I-MSH:D006223
tyrosine NN O I-MSH:D006223
phosphatase; NN O I-MSH:D006223
ptpase), NN O B-MSH:D006223
was NN O B-MSH:D006223
shown NN O O
recently NN O O
to NN O O
play NN O O
a NN O O
broad NN O O
role NN O O
in NN O O
human NN O O
malignancy NN B-DiseaseClass O
. NN O O
somatic NN O O

in NN O B-MSH:D006223
30 NN O B-MSH:D006223
of NN O B-MSH:D006223
37 NN O B-MSH:D006223
(81%) NN O O
CD NN B-Modifier O

studied. NN O B-MSH:D006223
interestingly, NN O B-MSH:D006223
none NN O B-MSH:D006223
of NN O B-MSH:D006223
these NN O B-MSH:D006223
mutations NN O B-MSH:D001941
was NN O I-MSH:D001941
observed NN O O
in NN O O
the NN O O
ptpase NN O O
core NN O O
motif. NN O O
it NN O O
is NN O O
also NN O O
worthy NN O O
of NN O O
note NN O O
that NN O O
a NN O O
single NN O O
nonsense NN O O
point NN O O
mutation, NN O O
r NN O O
233 NN O O
x, NN O O
was NN O O
observed NN O O
in NN O O
the NN O O
germline NN O O
dna NN O O
from NN O O
two NN O O
unrelated NN O O
CD NN B-Modifier O

observed NN O B-MSH:D001941
between NN O I-MSH:D001941
the NN O I-MSH:D001941
presence NN O B-MSH:D006223
of NN O O
a NN O O
pten NN O O

i NN O B-MSH:D003123
1307 NN O I-MSH:D003123
k NN O I-MSH:D003123
apc NN O I-MSH:D003123
and NN O O
hmlh NN O O

we NN O B-MSH:D003123
describe NN O I-MSH:D003123
a NN O I-MSH:D003123
french NN O I-MSH:D003123
canadian NN O B-MSH:D003123
hereditary NN B-Modifier I-MSH:D015179
non-polyposis NN I-Modifier B-MSH:D009369
colorectal NN I-Modifier O
cancer NN I-Modifier O

wilms' NN O O

products NN O B-MSH:D009396
of NN O I-MSH:D009396
steroidogenic NN O B-MSH:D058490
factor NN O I-MSH:D058490
1 NN O B-MSH:D030321
(sf-1) NN O I-MSH:D030321
and NN O O
Wilms NN B-Modifier O
tumor NN I-Modifier O
1 NN O O
(wt NN O O
1) NN O O
genes NN O O
are NN O O
essential NN O O
for NN O O
mammalian NN O O
gonadogenesis NN O O
prior NN O O
to NN O O
sexual NN O O
differentiation. NN O O
in NN O O
males, NN O O
sf-1 NN O O
participates NN O O
in NN O O
sexual NN O O
development NN O O
by NN O O
regulating NN O O
expression NN O O
of NN O O
the NN O O

1. NN O O

ethnic NN O O

recent NN O B-MSH:D006432
studies NN O I-MSH:D006432
have NN O B-MSH:D006432
shown NN O O
that NN O O
hereditary NN B-SpecificDisease O
hemochromatosis NN I-SpecificDisease O
( NN O O
HH NN B-SpecificDisease O
) NN O O
is NN O O
likely NN O O
to NN O O
be NN O O
caused NN O O
by NN O O
homozygosity NN O O
for NN O O
a NN O O
cys NN O O
282 NN O O
tyr NN O O
mutation NN O O
in NN O O
the NN O O
hfe NN O O
gene NN O O
located NN O O
4. NN O O
5 NN O O
mb NN O O
telomeric NN O O
to NN O O
hla-a. NN O O
population NN O O
studies NN O O
of NN O O
this NN O O
polymorphism NN O O
are NN O O
facilitated NN O O
by NN O O
the NN O O
fact NN O O
that NN O O
the NN O O
cys NN O O
282 NN O O
tyr NN O O
mutation NN O O
creates NN O O
a NN O O
rsal NN O O
restriction NN O O
site. NN O O
we NN O O
have NN O O
studied NN O O
the NN O O
codon NN O O
282 NN O O
(cys/tyr) NN O O
polymorphism NN O O
in NN O O
different NN O O
ethnic NN O O
groups. NN O O
in NN O O
agreement NN O O
with NN O O
previous NN O O
observations NN O O
the NN O O
tyr NN O O
allele NN O O
appeared NN O O
to NN O O
be NN O O
rare NN O O
or NN O O
absent NN O O
in NN O O
asiatic NN O O
(indian, NN O O
chinese) NN O O
populations. NN O O
the NN O O
highest NN O O
allele NN O O
frequency NN O O
(7. NN O O
5%) NN O O
was NN O O
found NN O O
in NN O O
swedes. NN O O
saamis NN O O
(2%) NN O O
and NN O O
mordvinians NN O O
(1. NN O O
8%) NN O O
had NN O O
significantly NN O O
lower NN O O
frequencies NN O O

frequencies NN O B-MSH:D006432
based NN O B-MSH:D006432
on NN O B-MSH:D009369
prevalence NN O O

risk NN O B-MSH:D006816
reversals NN O I-MSH:D006816
in NN O O
predictive NN O O

the NN O B-MSH:D006816
first NN O I-MSH:D006816
predictive NN O B-MSH:D006816
testing NN O B-MSH:D006816
for NN O B-MSH:D006816
Huntington NN B-SpecificDisease O
disease NN I-SpecificDisease O
( NN O O
HD NN B-SpecificDisease O
) NN O O
was NN O O
based NN O O
on NN O O
analysis NN O O
of NN O O
linked NN O O
polymorphic NN O O
dna NN O O
markers NN O O
to NN O O
estimate NN O O
the NN O O
likelihood NN O O
of NN O O
inheriting NN O O
the NN O O
mutation NN O O
for NN O O
HD NN B-SpecificDisease O
. NN O O
limits NN O O
to NN O O
accuracy NN O O
included NN O O
recombination NN O O
between NN O O
the NN O O
dna NN O O
markers NN O O
and NN O O
the NN O O
mutation, NN O O
pedigree NN O O
structure, NN O O
and NN O O
whether NN O O
dna NN O O
samples NN O O
were NN O O
available NN O O
from NN O O
family NN O O
members. NN O O
with NN O O
direct NN O O
tests NN O O
for NN O O
the NN O O
HD NN B-Modifier O
mutation, NN O O
we NN O O
have NN O O
assessed NN O O
the NN O O
accuracy NN O O
of NN O O
results NN O O
obtained NN O O
by NN O O
linkage NN O O
approaches NN O O
when NN O O
requested NN O O
to NN O O

team NN O O

identification NN O B-MSH:D006527
of NN O I-MSH:D006527
three NN O O
novel NN O O

four NN O B-MSH:D006527
mutations--r NN O I-MSH:D006527
778 NN O B-MSH:D006527
l, NN O I-MSH:D006527
a NN O O
874 NN O O

determination NN O B-MSH:C536587
of NN O I-MSH:C536587
the NN O I-MSH:C536587
genomic NN O I-MSH:C536587
structure NN O O
of NN O O

autosomal NN O B-MSH:D005921
recessive NN O I-MSH:D005921
alport NN O B-MSH:D005921
syndrome NN O I-MSH:D005921
is NN O I-MSH:D005921
a NN O I-MSH:D005921
progressive NN O B-MSH:C536587
hematuric NN B-SpecificDisease I-MSH:C536587
glomerulonephritis NN I-SpecificDisease I-MSH:C536587
characterized NN O O
by NN O O
glomerular NN B-DiseaseClass O
basement NN I-DiseaseClass O
membrane NN I-DiseaseClass O
abnormalities NN I-DiseaseClass O
and NN O O
associated NN O O
with NN O O
mutations NN O O
in NN O O
either NN O O
the NN O O
col NN O O
4 NN O O
a NN O O
3 NN O O
or NN O O
the NN O O
col NN O O
4 NN O O
a NN O O
4 NN O O
gene, NN O O
which NN O O

individuals, NN O O

a NN O B-MSH:D003920
gene NN O I-MSH:D003920
encoding NN O B-MSH:D009896
a NN O I-MSH:D009896
transmembrane NN O B-OMIM:222300
protein NN O I-OMIM:222300
is NN O O
mutated NN O O

wolfram NN O B-OMIM:222300
syndrome NN O B-MSH:D020271
( NN O I-MSH:D020271
WFS NN B-SpecificDisease I-MSH:D020271
; NN O I-MSH:D020271
omim NN O B-MSH:D003922
222300) NN O I-MSH:D003922
is NN O I-MSH:D003922
an NN O B-MSH:D009896
autosomal NN B-DiseaseClass B-OMIM:222300
recessive NN I-DiseaseClass B-OMIM:222300
neurodegenerative NN I-DiseaseClass O
disorder NN I-DiseaseClass O
defined NN O O
by NN O O
young-onset NN O O
non-immune NN O O
insulin-dependent NN B-SpecificDisease O
diabetes NN I-SpecificDisease O
mellitus NN I-SpecificDisease O
and NN O O
progressive NN O O
optic NN B-SpecificDisease O
atrophy NN I-SpecificDisease O
. NN O O
linkage NN O O
to NN O O
markers NN O O
on NN O O
chromosome NN O O
4 NN O O

molecular NN O B-OMIM:612446
defects NN O I-OMIM:612446
leading NN O I-OMIM:612446
to NN O I-OMIM:612446
human NN O O
complement NN B-SpecificDisease O
component NN I-SpecificDisease O
C6 NN I-SpecificDisease O
deficiency NN I-SpecificDisease O

complement NN O B-OMIM:612446
component NN O B-MSH:D008585
c NN O I-MSH:D008585
6 NN O B-OMIM:612446
deficiency NN O B-MSH:D008581
( NN O B-MSH:D016870
C6D NN B-SpecificDisease I-MSH:D016870
) NN O B-OMIM:612446
was NN O O
diagnosed NN O O
in NN O O
a NN O O
16-year-old NN O O
african-american NN O O
male NN O O
with NN O O
meningococcal NN B-SpecificDisease O
meningitis NN I-SpecificDisease O

premature NN O O

sperm NN O B-MSH:D005621
dna NN O I-MSH:D005621
analysis NN O B-MSH:D005621
in NN O O
a NN O O

friedreich NN O B-MSH:D005621
ataxia NN O O
is NN O O
usually NN O O
caused NN O O
by NN O O
an NN O O
expansion NN O O
of NN O O
a NN O O
gaa NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
intron NN O O
1 NN O O
of NN O O
the NN O O
FRDA NN B-Modifier O
gene. NN O O
occasionally, NN O O
a NN O O
fully NN O O
expanded NN O O
allele NN O O
has NN O O
been NN O O
found NN O O
to NN O O
arise NN O O
from NN O O
a NN O O
premutation NN O O
of NN O O
100 NN O O
or NN O O
less NN O O
triplet NN O O
repeats. NN O O
we NN O O
have NN O O
examined NN O O
the NN O O
sperm NN O O
dna NN O O
of NN O O
a NN O O
premutation NN O O
carrier. NN O O
this NN O O
mans NN O O
leucocyte NN O O
dna NN O O
showed NN O O
one NN O O
normal NN O O
allele NN O O
and NN O O
one NN O O
allele NN O O
of NN O O
approximately NN O O
100 NN O O
repeats. NN O O
his NN O O
sperm NN O O
showed NN O O
an NN O O
expanded NN O O
allele NN O O
in NN O O
a NN O O
tight NN O O
range NN O O
centering NN O O
on NN O O
a NN O O
size NN O O
of NN O O
approximately NN O O
320 NN O O
trinucleotide NN O O
repeats. NN O O
his NN O O
affected NN O O
son NN O O
has NN O O
repeat NN O O
sizes NN O O
of NN O O
1040 NN O O
and NN O O
540. NN O O
these NN O O
data NN O O
suggest NN O O
that NN O O
expansion NN O O
occurs NN O O
in NN O O
two NN O O
stages, NN O O
the NN O O
first NN O O
during NN O O
meiosis NN O O
followed NN O O
by NN O O
a NN O O
second NN O O
mitotic NN O O
expansion. NN O O

the NN O O

eye NN O B-MSH:D020754
movement NN O I-MSH:D020754
abnormalities NN O I-MSH:D020754
correlate NN O I-MSH:D020754
with NN O O
genotype NN O O

we NN O B-MSH:D020754
compared NN O I-MSH:D020754
horizontal NN O I-MSH:D020754
eye NN O I-MSH:D020754
movements NN O B-OMIM:164400
(visually NN O I-OMIM:164400
guided NN O I-OMIM:164400
saccades, NN O I-OMIM:164400
antisaccades, NN O I-OMIM:164400
and NN O B-OMIM:164400
smooth NN O B-OMIM:183090
pursuit) NN O B-MSH:D017827
in NN O B-MSH:D017827
control NN O I-MSH:D017827
subjects NN O B-MSH:D017827
(n NN O B-OMIM:164400
= NN O B-MSH:D002524
14) NN O B-OMIM:183090
and NN O O
patients NN O O
with NN O O
three NN O O
forms NN O O
of NN O O
autosomal NN O O
dominant NN O O
cerebellar NN B-DiseaseClass O
ataxias NN I-DiseaseClass O
type NN I-DiseaseClass O
I NN I-DiseaseClass O
spinocerebellar NN B-CompositeMention O
ataxias NN I-CompositeMention O
1 NN I-CompositeMention O
and NN I-CompositeMention O
2 NN I-CompositeMention O
( NN O O
SCA1 NN B-SpecificDisease O
, NN O O
n NN O O
= NN O O
11; NN O O
SCA2 NN B-SpecificDisease O
, NN O O
n NN O O
= NN O O
10) NN O O
and NN O O
SCA3 NN B-SpecificDisease O
/ NN O O
Machado-Joseph NN B-SpecificDisease O
disease NN I-SpecificDisease O
( NN O O

. NN O B-MSH:D017827
in NN O B-MSH:D009759
SCA3 NN B-SpecificDisease B-MSH:D009759
, NN O I-MSH:D009759
gaze-evoked NN B-SpecificDisease B-OMIM:183090
nystagmus NN I-SpecificDisease B-MSH:D017827
was NN O B-OMIM:183090
often NN O B-MSH:D017827
present NN O O
as NN O O
was NN O O
saccade NN O O
hypometria NN O O
and NN O O
smooth NN O O
pursuit NN O O
gain NN O O

clustering NN O B-MSH:D001260
of NN O B-MSH:D015458
missense NN O I-MSH:D015458
mutations NN O I-MSH:D015458
in NN O O
the NN O O

ataxia-telangiectasia NN O B-MSH:D001260
( NN O B-MSH:D030342
A-T NN B-SpecificDisease I-MSH:D030342
) NN O I-MSH:D030342
is NN O B-MSH:D009369
a NN O B-MSH:D008223
recessive NN B-DiseaseClass B-MSH:D001260
multi-system NN I-DiseaseClass B-MSH:D009369
disorder NN I-DiseaseClass B-MSH:D015461
caused NN O I-MSH:D015461
by NN O I-MSH:D015461
mutations NN O B-MSH:D015461
in NN O B-MSH:D007945
the NN O I-MSH:D007945
atm NN O B-MSH:D015458
gene NN O I-MSH:D015458
at NN O I-MSH:D015458
11 NN O B-MSH:D001260
q NN O B-MSH:D015461
22-q NN O B-MSH:D001260
23 NN O B-MSH:D007938
(ref. NN O O
3). NN O O
the NN O O
risk NN O O
of NN O O
cancer NN B-DiseaseClass O
, NN O O

the NN O B-MSH:D015461
region NN O B-MSH:D001260
corresponding NN O B-MSH:D009369
to NN O B-MSH:D007938
the NN O B-MSH:D009369
kinase NN O B-MSH:D016393
domain, NN O I-MSH:D016393
which NN O I-MSH:D016393
is NN O B-MSH:D016393
highly NN O B-MSH:D016393
conserved NN O O
in NN O O
atm-related NN O O
proteins NN O O
in NN O O
mouse, NN O O
yeast NN O O
and NN O O
drosophila. NN O O
the NN O O
resulting NN O O
amino-acid NN O O
substitutions NN O O
are NN O O
predicted NN O O
to NN O O
interfere NN O O
with NN O O
atp NN O O
binding NN O O
or NN O O
substrate NN O O

atm NN O B-MSH:D009369
in NN O B-MSH:D015461
the NN O I-MSH:D015461
majority NN O B-MSH:D009369
of NN O B-MSH:D015461
mutated NN O O
tumours NN B-DiseaseClass O
establishes NN O O
somatic NN O O

identification NN O B-OMIM:125700
of NN O I-OMIM:125700
a NN O I-OMIM:125700
novel NN O I-OMIM:125700
nonsense NN O O
mutation NN O O

familial NN O B-OMIM:125700
neurohypophyseal NN O B-MSH:D030342
diabetes NN O I-MSH:D030342
insipidus NN O I-MSH:D030342
( NN O B-OMIM:125700
FNDI NN B-SpecificDisease O
) NN O O
is NN O O
an NN O O
autosomal NN B-DiseaseClass O
dominant NN I-DiseaseClass O
disease NN I-DiseaseClass O
caused NN O O
by NN O O
deficiency NN O O
in NN O O
the NN O O
antidiuretic NN O O
hormone NN O O
arginine NN O O
vasopressin NN O O
(avp) NN O O
encoded NN O O
by NN O O
the NN O O
avp-neurophysin NN O O
ii NN O O
(avp-npii) NN O O
gene NN O O
on NN O O
chromosome NN O O
20 NN O O
p NN O O
13. NN O O
in NN O O
this NN O O
study, NN O O
we NN O O
analyzed NN O O
two NN O O
families NN O O
with NN O O
FNDI NN B-SpecificDisease O
using NN O O
direct NN O O
automated NN O O
fluorescent, NN O O
solid NN O O
phase, NN O O
single-stranded NN O O
dna NN O O
sequencing NN O O
of NN O O
pcr-amplified NN O O
avp-npii NN O O
dna. NN O O
in NN O O
one NN O O
of NN O O
the NN O O
families, NN O O
affected NN O O
individuals NN O O
presented NN O O
a NN O O
novel NN O O
nonsense NN O O
mutation NN O O
in NN O O
exon NN O O
3 NN O O
of NN O O

85, NN O B-OMIM:125700
which NN O O
could NN O O
be NN O O
involved NN O O
in NN O O
the NN O O
correct NN O O
folding NN O O
of NN O O
the NN O O
prohormone. NN O O
in NN O O
the NN O O
second NN O O
family, NN O O

cloning NN O O

a NN O B-MSH:D003922
gene NN O I-MSH:D003922
encoding NN O I-MSH:D003922
a NN O B-MSH:D003922
novel NN O B-MSH:D003920
transmembrane NN O O
protein NN O O
was NN O O
identified NN O O
by NN O O
dna NN O O
sequence NN O O
analysis NN O O
within NN O O
the NN O O
insulin-dependent NN B-Modifier O
diabetes NN I-Modifier O
mellitus NN I-Modifier O
( NN O O
IDDM NN B-Modifier O
) NN O O
locus NN O O
iddm NN O O
4 NN O O
on NN O O
chromosome NN O O
11 NN O O
q NN O O
13. NN O O
based NN O O
on NN O O
its NN O O
chromosomal NN O O
position, NN O O
this NN O O
gene NN O O
is NN O O
a NN O O
candidate NN O O
for NN O O
conferring NN O O
susceptibility NN O O
to NN O O
diabetes NN B-DiseaseClass O
. NN O O
the NN O O
gene, NN O O
termed NN O O
low-density NN O O
lipoprotein NN O O
receptor NN O O
related NN O O
protein NN O O
5 NN O O
(lrp NN O O
5), NN O O
encodes NN O O
a NN O O
protein NN O O
of NN O O
1615 NN O O
amino NN O O
acids NN O O
that NN O O
contains NN O O
conserved NN O O
modules NN O O
which NN O O
are NN O O
characteristic NN O O
of NN O O
the NN O O
low-density NN O O

a NN O O

atm NN O B-MSH:D001260
germline NN O O
mutations NN O O
in NN O O
classical NN O O
ataxia-telangiectasia NN B-Modifier O

germline NN O B-MSH:D030342
mutations NN O I-MSH:D030342
in NN O I-MSH:D030342
the NN O B-MSH:D001260
atm NN O B-MSH:D001260
gene NN O B-MSH:D001260
are NN O O
responsible NN O O
for NN O O
the NN O O
autosomal NN B-DiseaseClass O
recessive NN I-DiseaseClass O
disorder NN I-DiseaseClass O
ataxia-telangiectasia NN B-SpecificDisease O
( NN O O
A-T NN B-SpecificDisease O
). NN O O
in NN O O
our NN O O
study, NN O O
we NN O O
have NN O O
determined NN O O
the NN O O
atm NN O O
mutation NN O O
spectrum NN O O
in NN O O
19 NN O O
classical NN O O
A-T NN B-Modifier O
patients, NN O O
including NN O O
some NN O O
immigrant NN O O
populations, NN O O
as NN O O
well NN O O
as NN O O
12 NN O O
of NN O O
dutch NN O O
ethnic NN O O
origin. NN O O
both NN O O
the NN O O
protein NN O O
truncation NN O O
test NN O O
(ptt) NN O O
and NN O O
the NN O O
restriction NN O O
endonuclease NN O O
fingerprinting NN O O
(ref) NN O O
method NN O O
were NN O O
used NN O O
and NN O O
compared NN O O
for NN O O
their NN O O
detection NN O O
efficiency, NN O O
identifying NN O O
76% NN O O
and NN O O
60% NN O O
of NN O O
the NN O O
mutations, NN O O
respectively. NN O O
most NN O O
patients NN O O
were NN O O
found NN O O
to NN O O
be NN O O
compound NN O O
heterozygote. NN O O
seventeen NN O O
mutations NN O O

end NN O B-MSH:D001260
of NN O B-MSH:D001260
the NN O B-MSH:D001260
gene, NN O O
most NN O O
likely NN O O
a NN O O
result NN O O
of NN O O
recombination NN O O
between NN O O

diagnosis NN O B-MSH:D006432
of NN O O

if NN O B-MSH:D006432
untreated, NN O B-MSH:D003643
hemochromatosis NN B-SpecificDisease B-MSH:D019190
can NN O B-MSH:D008103
cause NN O B-MSH:D006432
serious NN O B-MSH:D006432
illness NN O O
and NN O O
early NN B-SpecificDisease O
death NN I-SpecificDisease O
, NN O O
but NN O O
the NN O O

with NN O B-MSH:D006432
a NN O B-MSH:D008103
proven NN O I-MSH:D008103
case NN O O
of NN O O
the NN O O
disease. NN O O
it NN O O
is NN O O
crucial NN O O
to NN O O
diagnose NN O O
hemochromatosis NN B-SpecificDisease O
before NN O O
hepatic NN B-SpecificDisease O
cirrhosis NN I-SpecificDisease O
develops NN O O
because NN O O

pax NN O O

mutations NN O B-MSH:D015783
in NN O B-MSH:C537884
pax NN O I-MSH:C537884
6 NN O B-MSH:D002386
are NN O I-MSH:D002386
responsible NN O B-MSH:C537022
for NN O I-MSH:C537022
human NN O I-MSH:C537022
aniridia NN B-SpecificDisease I-OMIM:136520
and NN O B-MSH:D015783
have NN O O
also NN O O
been NN O O
found NN O O
in NN O O
patients NN O O
with NN O O
Peters NN B-SpecificDisease O
anomaly NN I-SpecificDisease O
, NN O O
with NN O O
congenital NN B-SpecificDisease O
cataracts NN I-SpecificDisease O
, NN O O
with NN O O
autosomal NN B-SpecificDisease O
dominant NN I-SpecificDisease O
keratitis NN I-SpecificDisease O
, NN O O
and NN O O
with NN O O
isolated NN B-SpecificDisease O
foveal NN I-SpecificDisease O
hypoplasia NN I-SpecificDisease O
. NN O O
no NN O O
locus NN O O
other NN O O
than NN O O
chromosome NN O O
11 NN O O
p NN O O
13 NN O O
has NN O O
been NN O O
implicated NN O O
in NN O O
aniridia NN B-SpecificDisease O
, NN O O
and NN O O
pax NN O O
6 NN O O
is NN O O
clearly NN O O
the NN O O
major, NN O O
if NN O O
not NN O O
only, NN O O
gene NN O O
responsible. NN O O
twenty-eight NN O O
percent NN O O
of NN O O
identified NN O O
pax NN O O
6 NN O O
mutations NN O O
are NN O O
c-t NN O O
changes NN O O
at NN O O
cpg NN O O
dinucleotides, NN O O
20% NN O O
are NN O O
splicing NN O O
errors, NN O O
and NN O O
more NN O O
than NN O O
30% NN O O
are NN O O
deletion NN O O

appear NN O O
to NN O O
cause NN O O
loss NN O O
of NN O O
function NN O O
of NN O O
the NN O O

schwartz-jampel NN O B-MSH:C537502
syndrome NN O I-MSH:C537502
type NN O O
2 NN O O
and NN O O
Stuve-Wiedemann NN B-SpecificDisease O
syndrome NN I-SpecificDisease O

recent NN O B-MSH:D010009
studies NN O I-MSH:D010009
demonstrated NN O B-MSH:D010009
the NN O B-MSH:D009222
existence NN O B-MSH:C535662
of NN O I-MSH:C535662
a NN O B-MSH:C537502
genetically NN O I-MSH:C537502
distinct, NN O I-MSH:C537502
usually NN O B-MSH:C537502
lethal NN O I-MSH:C537502
form NN O B-MSH:C537502
of NN O B-MSH:C537966
the NN O B-MSH:C535662
Schwartz-Jampel NN B-SpecificDisease B-MSH:D003286
syndrome NN I-SpecificDisease B-MSH:D003643
( NN O B-MSH:C537502
SJS NN B-SpecificDisease I-MSH:C537502
) NN O I-MSH:C537502
of NN O B-MSH:C537502
myotonia NN B-SpecificDisease B-MSH:C537502
and NN O I-MSH:D009468
skeletal NN B-SpecificDisease I-MSH:D003286
dysplasia NN I-SpecificDisease I-MSH:D003286
, NN O O
which NN O O

respiratory NN O B-MSH:D005334
and NN O B-MSH:D055036
feeding NN O I-MSH:D055036
difficulties, NN O I-MSH:D055036
tendency NN O B-MSH:D001848
to NN O I-MSH:D001848
hyperthermia NN B-SpecificDisease I-MSH:C537502
, NN O I-MSH:C537502
and NN O B-MSH:C537502
frequent NN O B-MSH:C537502
death NN O B-MSH:C537502
in NN O I-MSH:C537502
infancy) NN O I-MSH:C537502
with NN O O
a NN O O
distinct NN O O
campomelic-metaphyseal NN B-SpecificDisease O
skeletal NN I-SpecificDisease O
dysplasia NN I-SpecificDisease O
. NN O O
the NN O O
similarity NN O O
of NN O O
the NN O O

the NN O O

the NN O B-OMIM:613399
185 NN O I-OMIM:613399
delag NN O I-OMIM:613399
mutation NN O I-OMIM:613399
in NN O I-OMIM:613399
brca NN O O
1 NN O O
is NN O O
detected NN O O
in NN O O
ashkenazi NN O O
jews NN O O
both NN O O
in NN O O
familial NN B-CompositeMention O
breast NN I-CompositeMention O
and NN I-CompositeMention O
ovarian NN I-CompositeMention O
cancer NN I-CompositeMention O
and NN O O
in NN O O
the NN O O
general NN O O
population. NN O O
all NN O O
tested NN O O
ashkenazi NN O O
mutation NN O O
carriers NN O O
share NN O O
the NN O O
same NN O O
allelic NN O O
pattern NN O O
at NN O O
the NN O O
brca NN O O
1 NN O O
locus. NN O O
our NN O O
previous NN O O
study NN O O
showed NN O O
that NN O O
this NN O O
ashkenazi NN O O
mutation NN O O
also NN O O
occurs NN O O
in NN O O
iraqi NN O O
jews NN O O
with NN O O
a NN O O
similar NN O O
allelic NN O O
pattern. NN O O
we NN O O
extended NN O O
our NN O O
analysis NN O O
to NN O O
other NN O O
non-ashkenazi NN O O
subsets NN O O
354 NN O O
of NN O O
moroccan NN O O
origin, NN O O
200 NN O O
yemenites NN O O
and NN O O
150 NN O O
iranian NN O O
jews. NN O O
heteroduplex NN O O
analysis NN O O
complemented NN O O
by NN O O
direct NN O O
dna NN O O
sequencing NN O O
of NN O O
abnormally NN O O
migrating NN O O
bands NN O O
were NN O O
employed. NN O O
four NN O O
of NN O O
moroccan NN O O
origin NN O O
(1. NN O O
1%) NN O O
and NN O O
none NN O O
of NN O O
the NN O O
yemenites NN O O
or NN O O
iranians NN O O
was NN O O
a NN O O
carrier NN O O
of NN O O
the NN O O
185 NN O O
delag NN O O
mutation. NN O O
brca NN O O
1 NN O O

185 NN O B-MSH:D061325
delag NN O I-MSH:D061325
mutation NN O O
carriers NN O O
who NN O O
had NN O O
breast/ovarian NN B-CompositeMention O
cancer NN I-CompositeMention O
. NN O O
six NN O O
non-ashkenazi NN O O
individuals NN O O
shared NN O O
the NN O O
common NN O O
ashkenazi NN O O
haplotype, NN O O
four NN O O
had NN O O
a NN O O
closely NN O O
related NN O O
pattern, NN O O
and NN O O
the NN O O
rest NN O O
(n NN O O
= NN O O
6) NN O O
displayed NN O O
a NN O O
distinct NN O O
brca NN O O
1 NN O O
allelic NN O O
pattern. NN O O
we NN O O
conclude NN O O
that NN O O
the NN O O
185 NN O O
delag NN O O
brca NN O O
1 NN O O
mutation NN O O
occurs NN O O
in NN O O
some NN O O
non-ashkenazi NN O O
populations NN O O
at NN O O
rates NN O O
comparable NN O O
with NN O O
that NN O O
of NN O O
ashkenazim. NN O O
the NN O O
majority NN O O
of NN O O
jewish NN O O
185 NN O O
delag NN O O
mutation NN O O
carriers NN O O
have NN O O
a NN O O
common NN O O
allelic NN O O
pattern, NN O O
supporting NN O O
the NN O O
founder NN O O
effect NN O O
notion, NN O O
but NN O O
dating NN O O
the NN O O
mutations NN O O
origin NN O O
to NN O O
an NN O O
earlier NN O O
date NN O O
than NN O O
currently NN O O
estimated. NN O O
however, NN O O
the NN O O
different NN O O
allelic NN O O
pattern NN O O
at NN O O
the NN O O
brca NN O O
1 NN O O
locus NN O O
even NN O O
in NN O O
some NN O O
jewish NN O O
mutation NN O O
carriers, NN O O
might NN O O

the NN O B-MSH:D012175
rb NN O I-MSH:D012175
1 NN O I-MSH:D012175
gene NN O O
mutation NN O O

the NN O B-MSH:D012175
rb NN O I-MSH:D012175
1 NN O I-MSH:D012175
gene NN O B-MSH:D019572
mutation NN O I-MSH:D019572
was NN O I-MSH:D019572
investigated NN O I-MSH:D019572
in NN O B-MSH:D019572
a NN O I-MSH:D019572
child NN O I-MSH:D019572
with NN O I-MSH:D019572
ectopic NN B-SpecificDisease B-MSH:D012175
intracranial NN I-SpecificDisease O
retinoblastoma NN I-SpecificDisease O

genomic NN O B-MSH:C536210
structure NN O I-MSH:C536210
of NN O I-MSH:C536210
the NN O B-MSH:C536210
human NN O O
congenital NN B-Modifier O

congenital NN O B-MSH:C536210
chloride NN O B-MSH:C536210
diarrhea NN O B-MSH:C536210
( NN O O
CLD NN B-SpecificDisease O
) NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
a NN O O
gene NN O O
which NN O O
encodes NN O O
an NN O O
intestinal NN O O
anion NN O O
transporter. NN O O
we NN O O
report NN O O
here NN O O
the NN O O
complete NN O O
genomic NN O O
organization NN O O
of NN O O
the NN O O
human NN O O
CLD NN B-Modifier O
gene NN O O
which NN O O
spans NN O O
approximately NN O O
39 NN O O
kb, NN O O
and NN O O
comprises NN O O
21 NN O O

gene NN O B-MSH:C536210
3 NN O B-MSH:C536648
of NN O I-MSH:C536648
the NN O B-MSH:C536648
CLD NN B-Modifier O

mutation NN O B-MSH:D017204
analysis NN O I-MSH:D017204
of NN O O
ube NN O O
3 NN O O

angelman NN O B-MSH:D017204
syndrome NN O B-MSH:D024182
( NN O I-MSH:D024182
AS NN B-SpecificDisease B-MSH:D024182
) NN O B-MSH:D017204
is NN O O
caused NN O O
by NN O O
chromosome NN O O
15 NN O O
q NN O O
11-q NN O O
13 NN O O
deletions NN O O
of NN O O
maternal NN O O
origin, NN O O
by NN O O
paternal NN O O
uniparental NN B-SpecificDisease O
disomy NN I-SpecificDisease O
( NN O O
UPD NN B-SpecificDisease O
) NN O O
15, NN O O
by NN O O
imprinting NN O O
defects, NN O O
and NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
ube NN O O
3 NN O O
a NN O O
gene. NN O O
ube NN O O
3 NN O O
a NN O O
encodes NN O O
a NN O O
ubiquitin-protein NN O O
ligase NN O O
and NN O O
shows NN O O
brain-specific NN O O
imprinting. NN O O
here NN O O
we NN O O
describe NN O O
ube NN O O
3 NN O O
a NN O O
coding-region NN O O
mutations NN O O
detected NN O O
by NN O O
sscp NN O O
analysis NN O O
in NN O O

domain NN O B-MSH:D017204
of NN O B-MSH:D017204
the NN O B-MSH:D017204
ube NN O O
3 NN O O
a NN O O
protein, NN O O
which NN O O
functions NN O O
in NN O O
e NN O O
2 NN O O
binding NN O O
and NN O O
ubiquitin NN O O
transfer. NN O O
eight NN O O
of NN O O
the NN O O
cases NN O O
were NN O O
familial, NN O O
and NN O O
five NN O O
were NN O O
sporadic. NN O O
in NN O O
two NN O O
familial NN O O

autosomal NN O O

autosomal NN O B-OMIM:125700
dominant NN O B-MSH:D030342
neurohypophyseal NN O I-MSH:D030342
diabetes NN O B-MSH:D003919
insipidus NN O I-MSH:D003919
( NN O B-OMIM:125700
ADNDI NN B-SpecificDisease O
) NN O O
is NN O O
an NN O O
inherited NN B-DiseaseClass O
disease NN I-DiseaseClass O
caused NN O O
by NN O O
progressive NN O O
degeneration NN O O
of NN O O
the NN O O
magnocellular NN O O
neurons NN O O
of NN O O
the NN O O
hypothalamus NN O O
leading NN O O
to NN O O
decreased NN O O
ability NN O O
to NN O O
produce NN O O
the NN O O
hormone NN O O
arginine NN O O
vasopressin NN O O
(avp). NN O O
affected NN O O
individuals NN O O
are NN O O
not NN O O
symptomatic NN O O
at NN O O
birth, NN O O
but NN O O
usually NN O O
develop NN O O
diabetes NN B-SpecificDisease O
insipidus NN I-SpecificDisease O
at NN O O
1-6 NN O O
yr NN O O
of NN O O
age. NN O O
the NN O O
genetic NN O O
locus NN O O
of NN O O

substitution NN O B-MSH:D020271
gly NN O I-MSH:D020271
23-- NN O I-MSH:D020271
> NN O O
val NN O O
within NN O O
npii. NN O O
the NN O O
mutation NN O O
was NN O O
confirmed NN O O
by NN O O
restriction NN O O
endonuclease NN O O
analysis. NN O O
a NN O O
t NN O O
1-weighted NN O O
magnetic NN O O
resonance NN O O
imaging NN O O
of NN O O
the NN O O
fathers NN O O
pituitary NN O O

reversal NN O B-MSH:D002312
of NN O I-MSH:D002312
severe NN O B-MSH:C536353
hypertrophic NN B-SpecificDisease I-MSH:C536353
cardiomyopathy NN I-SpecificDisease I-MSH:C536353
and NN O O
excellent NN O O

very-long-chain NN O B-MSH:C536353
acyl-coenzyme NN O I-MSH:C536353
a NN O B-MSH:D002312
dehydrogenase NN O I-MSH:D002312
(vlcad) NN O B-MSH:D006529
deficiency NN O B-MSH:D001927
is NN O B-MSH:D009123
a NN O B-MSH:C536353
disorder NN O I-MSH:C536353
of NN O O
fatty NN O O
acid NN O O
beta NN O O
oxidation NN O O
that NN O O
reportedly NN O O
has NN O O
high NN O O
rates NN O O
of NN O O
morbidity NN O O
and NN O O
mortality. NN O O
we NN O O
describe NN O O
the NN O O
outcome NN O O
of NN O O
a NN O O
5-year-old NN O O
girl NN O O
with NN O O
VLCAD NN B-SpecificDisease O
deficiency NN I-SpecificDisease O
who NN O O
was NN O O
first NN O O
seen NN O O
at NN O O
5 NN O O
months NN O O
of NN O O
age NN O O
with NN O O
severe NN O O
hypertrophic NN B-SpecificDisease O
cardiomyopathy NN I-SpecificDisease O
, NN O O
hepatomegaly NN B-SpecificDisease O
, NN O O
encephalopathy NN B-DiseaseClass O
, NN O O
and NN O O
hypotonia NN B-SpecificDisease O
. NN O O
biochemical NN O O
studies NN O O
indicated NN O O
VLCAD NN B-SpecificDisease O
deficiency NN I-SpecificDisease O
caused NN O O

fasting. NN O B-MSH:C536353
her NN O I-MSH:C536353
ventricular NN O B-MSH:D009202
hypertrophy NN O O
resolved NN O O
significantly NN O O
over NN O O

mutations NN O B-MSH:D001260
of NN O O
the NN O O
atm NN O O
gene NN O O
detected NN O O
in NN O O
japanese NN O O
ataxia-telangiectasia NN B-Modifier O
patients: NN O O
possible NN O O
preponderance NN O O
of NN O O
the NN O O
two NN O O
founder NN O O

the NN O B-MSH:D030342
atm NN O I-MSH:D030342
(a-t, NN O B-MSH:D001260
mutated) NN O B-MSH:D001260
gene NN O B-MSH:D001260
on NN O B-MSH:D001260
human NN O O
chromosome NN O O
11 NN O O
q NN O O
22. NN O O
3 NN O O
has NN O O
recently NN O O
been NN O O
identified NN O O
as NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
the NN O O
human NN O O
recessive NN B-DiseaseClass O
disease NN I-DiseaseClass O
ataxia-telangiectasia NN B-SpecificDisease O
( NN O O
A-T NN B-SpecificDisease O
). NN O O
in NN O O
order NN O O
to NN O O
define NN O O
the NN O O
types NN O O
of NN O O
disease-causing NN O O
atm NN O O
mutations NN O O
in NN O O
japanese NN O O
A-T NN B-Modifier O
patients NN O O
as NN O O
well NN O O
as NN O O
to NN O O
look NN O O
for NN O O
possible NN O O
mutational NN O O
hotspots, NN O O
reverse-transcribed NN O O
rna NN O O

a NN O O
single NN O O
exon NN O O
exon NN O O
7, NN O O
exon NN O O
16, NN O O
exon NN O O
33 NN O O
or NN O O
exon NN O O
35. NN O O
the NN O O
others NN O O
were NN O O
minute NN O O
deletions, NN O O
4649 NN O O
dela NN O O
in NN O O
exon NN O O
33 NN O O
and NN O O
7883 NN O O
del NN O O
5 NN O O
in NN O O
exon NN O O
55. NN O O
the NN O O
mutations NN O O
4612 NN O O
del NN O O
165 NN O O
and NN O O
7883 NN O O
del NN O O
5 NN O O
were NN O O
found NN O O
in NN O O
more NN O O

down-regulation NN O B-MSH:D002292
of NN O I-MSH:D002292
transmembrane NN O I-MSH:D002292
carbonic NN O B-MSH:D006623
anhydrases NN O I-MSH:D006623
in NN O O
renal NN B-Modifier O

to NN O B-MSH:D006623
discover NN O I-MSH:D006623
genes NN O B-MSH:D006623
involved NN O B-MSH:D002292
in NN O I-MSH:D002292
von NN B-Modifier B-MSH:D006623
Hippel-Lindau NN I-Modifier B-MSH:D002292
( NN O I-MSH:D002292
VHL NN B-Modifier B-MSH:D006623
) NN O O
-mediated NN O O
carcinogenesis, NN O O
we NN O O
used NN O O
renal NN B-Modifier O

ca NN O B-MSH:D009369
12 NN O B-MSH:D009369
expression, NN O O
the NN O O
elongin NN O O
binding NN O O

a NN O B-OMIM:253000
novel NN O I-OMIM:253000
common NN O O
missense NN O O

mucopolysaccharidosis NN O B-OMIM:253000
iva NN O I-OMIM:253000
( NN O B-MSH:D016464
MPS NN B-SpecificDisease I-MSH:D016464
IVA NN I-SpecificDisease I-MSH:D016464
) NN O I-MSH:D016464
is NN O I-MSH:D016464
an NN O B-MSH:D030342
autosomal NN B-DiseaseClass B-OMIM:253000
recessive NN I-DiseaseClass I-OMIM:253000
lysosomal NN I-DiseaseClass B-OMIM:253000
storage NN I-DiseaseClass I-OMIM:253000
disorder NN I-DiseaseClass O
caused NN O O
by NN O O
a NN O O
genetic NN B-DiseaseClass O
defect NN I-DiseaseClass O
in NN O O
n-acetylgalactosamine-6-sulfate NN O O
sulfatase NN O O
(galns). NN O O
in NN O O
previous NN O O
studies, NN O O
we NN O O
have NN O O
found NN O O
two NN O O
common NN O O
mutations NN O O
in NN O O
caucasians NN O O
and NN O O
japanese, NN O O
respectively. NN O O

% NN O O

w NN O B-MSH:D020143
474 NN O I-MSH:D020143
c NN O O
amino NN O O

mutations NN O B-MSH:D013661
in NN O I-MSH:D013661
the NN O B-MSH:D013661
hexa NN O B-MSH:D020143
gene, NN O I-MSH:D020143
encoding NN O I-MSH:D020143
the NN O I-MSH:D020143
alpha-subunit NN O I-MSH:D020143
of NN O I-MSH:D020143
beta-hexosaminidase NN O I-MSH:D020143
a NN O I-MSH:D020143
(hex NN O B-MSH:D020143
a), NN O I-MSH:D020143
that NN O I-MSH:D020143
abolish NN O O
hex NN O O
a NN O O
enzyme NN O O
activity NN O O
cause NN O O
Tay-Sachs NN B-SpecificDisease O

, NN O B-MSH:D013661
we NN O O
identified NN O O
the NN O O
common NN O O
infantile NN O O
disease-causing NN O O

of NN O B-MSH:D013661
the NN O I-MSH:D013661
w NN O I-MSH:D013661
474 NN O I-MSH:D013661
c NN O B-MSH:D013661
alpha-subunit NN O I-MSH:D013661
was NN O I-MSH:D013661
found NN O O
to NN O O
accumulate NN O O
in NN O O
comparison NN O O

myotonic NN O O

myotonic NN O B-MSH:D009223
dystrophy NN O B-MSH:D009135
( NN O I-MSH:D009135
DM NN B-SpecificDisease B-MSH:D009223
), NN O O
the NN O O
most NN O O
prevalent NN O O
muscular NN B-DiseaseClass O
disorder NN I-DiseaseClass O
in NN O O
adults, NN O O
is NN O O
caused NN O O
by NN O O
(ctg) NN O O
n-repeat NN O O
expansion NN O O
in NN O O
a NN O O
gene NN O O
encoding NN O O
a NN O O
protein NN O O
kinase NN O O
( NN O O
DM NN B-Modifier O
protein NN O O
kinase; NN O O
dmpk) NN O O
and NN O O
involves NN O O
changes NN O O
in NN O O
cytoarchitecture NN O O
and NN O O
ion NN O O
homeostasis. NN O O
to NN O O
obtain NN O O
clues NN O O
to NN O O
the NN O O
normal NN O O
biological NN O O
role NN O O
of NN O O
dmpk NN O O
in NN O O
cellular NN O O
ion NN O O
homeostasis, NN O O
we NN O O
have NN O O
compared NN O O
the NN O O
resting NN O O
[ca NN O O
2 NN O O
+] NN O O
i, NN O O
the NN O O
amplitude NN O O
and NN O O
shape NN O O
of NN O O
depolarization-induced NN O O
ca NN O O
2 NN O O
+ NN O O
transients, NN O O
and NN O O
the NN O O
content NN O O
of NN O O
atp-driven NN O O
ion NN O O
pumps NN O O
in NN O O
cultured NN O O
skeletal NN O O
muscle NN O O

type NN O O
myotubes NN O O
because NN O O
of NN O O
an NN O O
altered NN O O
open NN O O
probability NN O O
of NN O O
voltage-dependent NN O O
l-type NN O O
ca NN O O
2 NN O O
+ NN O O
and NN O O
na NN O O
+ NN O O
channels. NN O O
the NN O O
mutant NN O O
myotubes NN O O
exhibit NN O O
smaller NN O O
and NN O O
slower NN O O
ca NN O O
2 NN O O
+ NN O O
responses NN O O
upon NN O O
triggering NN O O
by NN O O
acetylcholine NN O O
or NN O O
high NN O O
external NN O O
k NN O O
+. NN O O
in NN O O
addition, NN O O
we NN O O
observed NN O O
that NN O O
these NN O O
ca NN O O
2 NN O O
+ NN O O
transients NN O O
partially NN O O
result NN O O
from NN O O
an NN O O
influx NN O O
of NN O O
extracellular NN O O
ca NN O O
2 NN O O
+ NN O O
through NN O O
the NN O O
l-type NN O O
ca NN O O
2 NN O O
+ NN O O
channel. NN O O
neither NN O O
the NN O O
content NN O O
nor NN O O
the NN O O
activity NN O O
of NN O O
na NN O O
+/k NN O O
+ NN O O
atpase NN O O
and NN O O
sarcoplasmic NN O O
reticulum NN O O
ca NN O O
2 NN O O
+ NN O O
-atpase NN O O
are NN O O
affected NN O O

insertional NN O B-MSH:D020388
mutation NN O B-MSH:D002311
by NN O I-MSH:D002311
transposable NN O I-MSH:D002311
element, NN O O
l NN O O

x-linked NN O B-MSH:D002311
dilated NN O B-MSH:D009136
cardiomyopathy NN O B-MSH:D009202
( NN O I-MSH:D009202
XLDCM NN B-SpecificDisease B-MSH:D009135
) NN O I-MSH:D009135
is NN O B-MSH:D020388
a NN O I-MSH:D020388
clinical NN O I-MSH:D020388
phenotype NN O B-MSH:D002311
of NN O B-MSH:D002311
dystrophinopathy NN B-DiseaseClass O
which NN O O
is NN O O
characterized NN O O
by NN O O
preferential NN O O
myocardial NN B-DiseaseClass O
involvement NN I-DiseaseClass O
without NN O O
any NN O O
overt NN O O
clinical NN O O
signs NN O O
of NN O O
skeletal NN B-SpecificDisease O
myopathy NN I-SpecificDisease O
. NN O O
to NN O O
date, NN O O
several NN O O
mutations NN O O
in NN O O
the NN O O
Duchenne NN B-Modifier O
muscular NN I-Modifier O
dystrophy NN I-Modifier O
gene, NN O O
dmd, NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
patients NN O O
with NN O O

dystrophin NN O B-MSH:D002311
transcripts NN O O
but NN O O

genetic NN O B-OMIM:101400
heterogeneity NN O I-OMIM:101400
of NN O O
Saethre-Chotzen NN B-SpecificDisease O
syndrome NN I-SpecificDisease O
, NN O O
due NN O O
to NN O O
twist NN O O

thirty-two NN O B-OMIM:101400
unrelated NN O I-OMIM:101400
patients NN O B-MSH:D030342
with NN O I-MSH:D030342
features NN O I-MSH:D030342
of NN O B-MSH:D003398
Saethre-Chotzen NN B-SpecificDisease I-MSH:D017880
syndrome NN I-SpecificDisease B-OMIM:101400
, NN O I-OMIM:101400
a NN O O
common NN O O
autosomal NN B-DiseaseClass O
dominant NN I-DiseaseClass O
condition NN I-DiseaseClass O
of NN O O
craniosynostosis NN B-SpecificDisease O
and NN O O
limb NN B-DiseaseClass O
anomalies NN I-DiseaseClass O
, NN O O
were NN O O
screened NN O O
for NN O O
mutations NN O O
in NN O O
twist, NN O O
fgfr NN O O
2, NN O O
and NN O O
fgfr NN O O
3. NN O O
nine NN O O
novel NN O O
and NN O O
three NN O O
recurrent NN O O
twist NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O

patients NN O B-MSH:D003398
with NN O I-MSH:D003398
twist NN O B-MSH:D003398
mutations, NN O B-MSH:D019465
are NN O I-MSH:D019465
coronal NN B-SpecificDisease B-MSH:D005146
synostosis NN I-SpecificDisease I-MSH:D005146
, NN O B-MSH:D001763
brachycephaly NN B-SpecificDisease B-MSH:D005532
, NN O I-MSH:D005532
low NN B-SpecificDisease B-MSH:C536852
frontal NN I-SpecificDisease B-MSH:D003398
hairline NN I-SpecificDisease I-MSH:D003398
, NN O B-OMIM:101400
facial NN B-SpecificDisease I-OMIM:101400
asymmetry NN I-SpecificDisease I-OMIM:101400
, NN O I-OMIM:101400
ptosis NN B-SpecificDisease O
, NN O O
hypertelorism NN B-SpecificDisease O
, NN O O
broad NN B-SpecificDisease O
great NN I-SpecificDisease O
toes NN I-SpecificDisease O
, NN O O
and NN O O
clinodactyly NN B-SpecificDisease O
. NN O O
significant NN O O
intra- NN O O
and NN O O
interfamilial NN O O
phenotypic NN O O
variability NN O O
is NN O O
present NN O O
for NN O O
either NN O O
twist NN O O

frequent NN O B-MSH:D011471
inactivation NN O I-MSH:D011471
of NN O O
pten/mmac NN O O

sporadic NN O B-MSH:D005834
prostate NN O I-MSH:D005834
carcinoma NN O B-MSH:D009369
is NN O B-MSH:D011471
the NN O I-MSH:D011471
most NN O I-MSH:D011471
common NN O B-MSH:D009369
male NN B-DiseaseClass I-MSH:D011471
cancer NN I-DiseaseClass B-MSH:D011471
in NN O O
the NN O O
western NN O O
world, NN O O
yet NN O O
many NN O O
of NN O O
the NN O O
major NN O O
genetic NN O O
events NN O O
involved NN O O
in NN O O
the NN O O
progression NN O O
of NN O O
this NN O O
often NN O O
fatal NN O O
cancer NN B-DiseaseClass O
remain NN O O

of NN O B-MSH:D009369
the NN O B-MSH:D011471
entire NN O I-MSH:D011471
pten/mmac NN O I-MSH:D011471
1 NN O O
coding NN O O

molecular NN O B-OMIM:253000
heterogeneity NN O I-OMIM:253000
in NN O O
mucopolysaccharidosis NN B-SpecificDisease O
IVA NN I-SpecificDisease O
in NN O O
australia NN O O
and NN O O
northern NN O O
ireland: NN O O
nine NN O O
novel NN O O
mutations NN O O
including NN O O
t NN O O
312 NN O O
s, NN O O
a NN O O
common NN O O
allele NN O O
that NN O O
confers NN O O

mucopolysaccharidosis NN O B-OMIM:253000
iva NN O I-OMIM:253000
( NN O B-MSH:D016464
MPS NN B-SpecificDisease I-MSH:D016464
IVA NN I-SpecificDisease I-MSH:D016464
) NN O I-MSH:D016464
is NN O I-MSH:D016464
an NN O B-MSH:D030342
autosomal NN B-DiseaseClass B-OMIM:253000
recessive NN I-DiseaseClass I-OMIM:253000
lysosomal NN I-DiseaseClass B-OMIM:253000
storage NN I-DiseaseClass I-OMIM:253000
disorder NN I-DiseaseClass O
caused NN O O
by NN O O
a NN O O
genetic NN B-DiseaseClass O
defect NN I-DiseaseClass O
in NN O O
n-acetylgalactosamine-6-sulfate NN O O
sulfatase NN O O
(galns). NN O O
previous NN O O
studies NN O O
of NN O O
patients NN O O
from NN O O
a NN O O
british-irish NN O O
population NN O O
showed NN O O
that NN O O
the NN O O
i NN O O
113 NN O O
f NN O O
mutation NN O O
is NN O O
the NN O O
most NN O O
common NN O O
single NN O O
mutation NN O O
among NN O O
MPS NN B-Modifier O
IVA NN I-Modifier O
patients NN O O
and NN O O
produces NN O O
a NN O O
severe NN O O
clinical NN O O
phenotype. NN O O
we NN O O
studied NN O O
mutations NN O O
in NN O O

mutation NN O O
found NN O O
exclusively NN O O
in NN O O
milder NN O O
patients. NN O O
the NN O O
other NN O O
is NN O O
the NN O O
previously NN O O
described NN O O
i NN O O
113 NN O O
f NN O O
that NN O O
produces NN O O
a NN O O
severe NN O O
phenotype. NN O O
the NN O O
i NN O O
113 NN O O
f NN O O
and NN O O
t NN O O
312 NN O O
s NN O O
mutations NN O O
accounted NN O O
for NN O O
8 NN O O
(18%) NN O O
and NN O O
6 NN O O
(14%) NN O O
of NN O O
44 NN O O
unrelated NN O O
alleles, NN O O
respectively. NN O O
the NN O O
relatively NN O O
high NN O O
residual NN O O
galns NN O O
activity NN O O
seen NN O O
when NN O O
the NN O O
t NN O O
312 NN O O
s NN O O
mutant NN O O
cdna NN O O

data NN O B-OMIM:253000
that NN O I-OMIM:253000
the NN O O
i NN O O
113 NN O O
f NN O O
mutation NN O O
originated NN O O
from NN O O
a NN O O
common NN O O
ancestor. NN O O
the NN O O
other NN O O
9 NN O O
novel NN O O
mutations NN O O
identified NN O O

further NN O B-MSH:D009223
evidence NN O I-MSH:D009223
for NN O O
a NN O O
major NN O O
ancient NN O O
mutation NN O O
underlying NN O O
myotonic NN B-SpecificDisease O
dystrophy NN I-SpecificDisease O

the NN O B-MSH:D009223
myotonic NN B-Modifier B-MSH:D009223
dystrophy NN I-Modifier B-MSH:D009223
( NN O B-MSH:D009223
DM NN B-Modifier B-MSH:D009223
) NN O O
mutation NN O O
is NN O O
an NN O O
unstable NN O O
(ctg) NN O O
n NN O O
repeat, NN O O
present NN O O
at NN O O
a NN O O
copy NN O O
number NN O O
of NN O O
5-37 NN O O
repeats NN O O
on NN O O
normal NN O O
chromosomes NN O O
but NN O O
amplified NN O O
to NN O O
50-3000 NN O O
copies NN O O
on NN O O
DM NN B-Modifier O
chromosomes. NN O O
previous NN O O
findings NN O O
in NN O O
caucasian NN O O
populations NN O O
of NN O O

dm NN O B-MSH:D009223
families NN O B-MSH:D005621
comprising NN O I-MSH:D005621
190 NN O O
affected NN O O

prevalence NN O B-MSH:D008545
of NN O B-MSH:D008545
p NN O I-MSH:D008545
16 NN O O
and NN O O
cdk NN O O
4 NN O O

germline NN O B-MSH:D008545
mutations NN O B-MSH:D008545
in NN O O
the NN O O
p NN O O
16 NN O O
and NN O O
cdk NN O O
4 NN O O
genes NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
a NN O O
subset NN O O
of NN O O
melanoma NN B-Modifier O
pedigrees, NN O O
but NN O O
their NN O O
prevalence NN O O
is NN O O
not NN O O
well NN O O
known. NN O O
we NN O O
searched NN O O
for NN O O
such NN O O
germline NN O O
mutations NN O O
in NN O O
48 NN O O
french NN O O
melanoma NN B-Modifier O
-prone NN O O
families NN O O
selected NN O O
according NN O O
to NN O O
two NN O O
major NN O O
criteria NN O O
families NN O O
with NN O O
at NN O O
least NN O O
three NN O O
affected NN O O
members NN O O
(n NN O O
= NN O O
20) NN O O
or NN O O
families NN O O
with NN O O
two NN O O
affected NN O O
members, NN O O
one NN O O
of NN O O
them NN O O
affected NN O O
before NN O O
the NN O O
age NN O O
of NN O O
50 NN O O
(n NN O O
= NN O O
28), NN O O
and NN O O
one NN O O
additional NN O O
minor NN O O
criterion. NN O O
sixteen NN O O
different NN O O
p NN O O
16 NN O O
germline NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
21 NN O O

4 NN O B-MSH:D008545
mutation NN O I-MSH:D008545
is NN O B-MSH:D008545
the NN O O
second NN O O
mutation NN O O

systematic NN O B-MSH:D046349
analysis NN O I-MSH:D046349
of NN O O
coproporphyrinogen NN O O
oxidase NN O O
gene NN O O
defects NN O O

hereditary NN O B-MSH:D046349
coproporphyria NN O B-MSH:D017094
( NN O I-MSH:D017094
HC NN B-SpecificDisease B-MSH:D046349
) NN O I-MSH:D046349
is NN O I-MSH:D046349
an NN O I-MSH:D046349
acute NN O I-MSH:D046349
hepatic NN B-SpecificDisease B-MSH:D009422
porphyria NN I-SpecificDisease I-MSH:D009422
with NN O I-MSH:D003141
autosomal NN O B-MSH:D046349
dominant NN O O
inheritance NN O O
caused NN O O
by NN O O
deficient NN B-SpecificDisease O
activity NN I-SpecificDisease O
of NN I-SpecificDisease O
coproporphyrinogen NN I-SpecificDisease O
III NN I-SpecificDisease O
oxidase NN I-SpecificDisease O
(cpo). NN O O
clinical NN O O
manifestations NN O O
of NN O O
the NN O O
disease NN O O
are NN O O
characterized NN O O
by NN O O
acute NN O O
attacks NN O O
of NN O O
neurological NN B-DiseaseClass O
dysfunction NN I-DiseaseClass O
often NN O O
precipitated NN O O

r), NN O O

bp NN O B-MSH:D046349
upstream NN O B-MSH:D030342
from NN O I-MSH:D030342
the NN O O
transcriptional NN O O
initiation NN O O
site NN O O
(-142 NN O O

the NN O B-MSH:D000740
haptoglobin-gene NN O O
deletion NN O O

we NN O B-MSH:D000740
have NN O B-MSH:D000740
found NN O B-MSH:D000740
an NN O O
allelic NN O O
deletion NN O O
of NN O O
the NN O O
haptoglobin NN O O
(hp) NN O O
gene NN O O
from NN O O
an NN O O
individual NN O O
with NN O O
anhaptoglobinemia NN B-SpecificDisease O
. NN O O
the NN O O
hp NN O O
gene NN O O
cluster NN O O
consists NN O O

hpdel. NN O B-MSH:D000740
the NN O B-MSH:D000740
phenotypes NN O O
and NN O O
genotypes NN O O
in NN O O
one NN O O
of NN O O
these NN O O
three NN O O
families NN O O
showed NN O O
the NN O O
father NN O O
to NN O O
be NN O O
hypohaptoglobinemic NN B-Modifier O
(hp NN O O
2) NN O O
and NN O O
hp NN O O
2/hpdel, NN O O
the NN O O
mother NN O O
to NN O O
be NN O O
hp NN O O
2-1 NN O O
and NN O O
hp NN O O
1/hp NN O O
2, NN O O
one NN O O
of NN O O
the NN O O
two NN O O
children NN O O
to NN O O
be NN O O
hypohaptoglobinemic NN B-Modifier O
(hp NN O O
2) NN O O
and NN O O
hp NN O O
2/hpdel, NN O O
and NN O O
the NN O O
other NN O O
child NN O O
to NN O O
be NN O O
hp NN O O
1 NN O O
and NN O O
hp NN O O
1/hpdel, NN O O
showing NN O O
an NN O O

07 NN O B-MSH:D000740
mg/ml) NN O B-MSH:D000740
obtained NN O O
from NN O O
52 NN O O

unknow NN O O

genotype-phenotype NN O B-MSH:C538265
correlations NN O I-MSH:C538265
in NN O I-MSH:C538265
attenuated NN B-SpecificDisease O
adenomatous NN I-SpecificDisease O

germ-line NN O B-MSH:D009369
mutations NN O B-MSH:C538265
of NN O I-MSH:C538265
the NN O I-MSH:C538265
tumor NN B-Modifier B-MSH:C538265
suppressor NN O I-MSH:D011125
apc NN O I-MSH:D011125
are NN O B-MSH:D011125
implicated NN O B-MSH:C538265
in NN O B-MSH:D018256
attenuated NN B-SpecificDisease B-MSH:D015179
adenomatous NN I-SpecificDisease I-MSH:D015179
polyposis NN I-SpecificDisease B-MSH:C538265
coli NN I-SpecificDisease B-MSH:D011125
( NN O B-MSH:D011125
AAPC NN B-SpecificDisease B-MSH:D011125
), NN O O
a NN O O
variant NN O O
of NN O O
familial NN B-SpecificDisease O
adenomatous NN I-SpecificDisease O
polyposis NN I-SpecificDisease O
( NN O O
FAP NN B-SpecificDisease O
). NN O O

and NN O B-MSH:D018256
5, NN O I-MSH:D018256
(2) NN O B-MSH:D000236
within NN O B-MSH:C538265
exon NN O B-MSH:D018256
9, NN O I-MSH:D018256
and NN O B-MSH:D011127
(3) NN O I-MSH:D011127
at NN O B-MSH:D018222
the NN O I-MSH:D018222
3 NN O B-MSH:C538265
distal NN O B-MSH:D011125
end NN O O
of NN O O
the NN O O
gene. NN O O
variability NN O O
in NN O O
the NN O O
number NN O O
of NN O O

. NN O B-MSH:D011125
this NN O O
should NN O O
help NN O O

the NN O B-MSH:D011125
APC NN B-Modifier I-MSH:D015179
variants NN O O
i NN O O
1307 NN O O
k NN O O
and NN O O
e NN O O
1317 NN O O
q NN O O

classical NN O B-MSH:D011125
familial NN B-SpecificDisease I-MSH:D011125
adenomatous NN I-SpecificDisease B-MSH:D011125
polyposis NN I-SpecificDisease B-MSH:D030342
( NN O I-MSH:D030342
FAP NN B-SpecificDisease B-MSH:D018256
) NN O I-MSH:D018256
is NN O I-MSH:D018256
a NN O I-MSH:D018256
high-penetrance NN O B-MSH:D011125
autosomal NN B-DiseaseClass B-MSH:C538265
dominant NN I-DiseaseClass I-MSH:C538265
disease NN I-DiseaseClass I-MSH:C538265
that NN O B-MSH:D011125
predisposes NN O B-MSH:C538265
to NN O I-MSH:C538265
hundreds NN O I-MSH:C538265
or NN O I-MSH:C538265
thousands NN O B-MSH:D000236
of NN O I-MSH:D000236
colorectal NN B-CompositeMention B-MSH:D000236
adenomas NN I-CompositeMention B-MSH:D011125
and NN I-CompositeMention B-MSH:D011125
carcinoma NN I-CompositeMention O
and NN O O
that NN O O
results NN O O
from NN O O
truncating NN O O

that NN O B-MSH:D015179
confers NN O I-MSH:D015179
an NN O B-MSH:D000236
increased NN O B-MSH:D018256
risk NN O I-MSH:D018256
of NN O I-MSH:D018256
colorectal NN B-SpecificDisease B-MSH:D011125
tumors NN I-SpecificDisease B-MSH:D003111
, NN O I-MSH:D003111
including NN O I-MSH:D003111
multiple NN O I-MSH:D003111
adenomas NN B-DiseaseClass B-MSH:D011125
, NN O B-MSH:D018256
in NN O I-MSH:D018256
ashkenazim. NN O I-MSH:D018256
we NN O I-MSH:D018256
have NN O O
studied NN O O
a NN O O
set NN O O
of NN O O
164 NN O O
patients NN O O
with NN O O
multiple NN O O

fap, NN O B-MSH:D015179
and NN O I-MSH:D015179
possibly NN O O
with NN O O
importance NN O O
for NN O O
colorectal NN B-SpecificDisease O
cancer NN I-SpecificDisease O

the NN O B-MSH:D006432
hemochromatosis NN B-Modifier O
845 NN O O
g-->a NN O O
and NN O O
187 NN O O
c-->g NN O O
mutations: NN O O
prevalence NN O O
in NN O O
non-caucasian NN O O

hemochromatosis, NN O B-MSH:D019189
the NN O I-MSH:D019189
inherited NN B-DiseaseClass I-MSH:D019189
disorder NN I-DiseaseClass I-MSH:D019189
of NN I-DiseaseClass B-MSH:D019190
iron NN I-DiseaseClass I-MSH:D019190
metabolism NN I-DiseaseClass B-MSH:D003643
, NN O I-MSH:D003643
leads, NN O B-MSH:D006432
if NN O B-MSH:D006432
untreated, NN O O
to NN O O
progressive NN O O
iron NN B-SpecificDisease O
overload NN I-SpecificDisease O
and NN O O
premature NN B-SpecificDisease O
death NN I-SpecificDisease O
. NN O O
the NN O O
hemochromatosis NN B-Modifier O
gene, NN O O
hfe, NN O O
recently NN O O
has NN O O
been NN O O
identified, NN O O
and NN O O
characterization NN O O
of NN O O
this NN O O
gene NN O O
has NN O O
shown NN O O
that NN O O
it NN O O
contains NN O O
two NN O O
mutations NN O O
that NN O O
result NN O O
in NN O O
amino NN O O
acid NN O O
substitutions-cdna NN O O
nucleotides NN O O
845 NN O O
g-- NN O O
> NN O O
a NN O O
(c NN O O
282 NN O O
y) NN O O
and NN O O

samples NN O O
from NN O O
non-caucasian NN O O
populations, NN O O
comprising NN O O
australian NN O O
aboriginal, NN O O
chinese, NN O O
and NN O O
pacific NN O O
islanders. NN O O
results NN O O
showed NN O O
that NN O O
the NN O O
845 NN O O
g-- NN O O
> NN O O
a NN O O
mutation NN O O
was NN O O
present NN O O
in NN O O
these NN O O
populations NN O O
(allele NN O O
frequency NN O O
0. NN O O
32%), NN O O
and, NN O O
furthermore, NN O O
it NN O O
was NN O O
always NN O O
seen NN O O
in NN O O
conjunction NN O O
with NN O O
hla NN O O
haplotypes NN O O
common NN O O
in NN O O
caucasians, NN O O
suggesting NN O O
that NN O O
845 NN O O
g-- NN O O
> NN O O
a NN O O
may NN O O
have NN O O
been NN O O

in NN O O

brca NN O O

the NN O B-MSH:D061325
breast NN B-Modifier I-MSH:D061325
and NN I-Modifier I-MSH:D061325
ovarian NN I-Modifier B-OMIM:604370
cancer NN I-Modifier I-OMIM:604370
susceptibility NN O O
gene NN O O
brca NN O O
1 NN O O
encodes NN O O
a NN O O
zinc NN O O
finger NN O O
protein NN O O
of NN O O
unknown NN O O
function. NN O O
association NN O O
of NN O O
the NN O O
brca NN O O
1 NN O O
protein NN O O
with NN O O
the NN O O
dna NN O O
repair NN O O
protein NN O O
rad NN O O
51 NN O O
and NN O O
changes NN O O
in NN O O
the NN O O
phosphorylation NN O O
and NN O O
cellular NN O O
localization NN O O
of NN O O
the NN O O
protein NN O O
after NN O O
exposure NN O O
to NN O O
dna-damaging NN O O
agents NN O O
are NN O O

a NN O B-MSH:D014842
mouse NN O I-MSH:D014842
model NN O I-MSH:D014842
of NN O B-MSH:D013927
severe NN O O

von NN O B-MSH:D014842
willebrand NN O I-MSH:D014842
factor NN O I-MSH:D014842
(vwf) NN O B-MSH:C531844
deficiency NN O B-MSH:D014842
causes NN O I-MSH:D014842
severe NN O B-MSH:D013927
von NN B-SpecificDisease I-MSH:D057772
Willebrand NN I-SpecificDisease O
disease NN I-SpecificDisease O

this NN O B-MSH:D014842
model, NN O I-MSH:D014842
the NN O I-MSH:D014842
exteriorized NN O O
mesentery NN O O
was NN O O
superfused NN O O
with NN O O
ferric NN O O
chloride NN O O
and NN O O
the NN O O
accumulation NN O O
of NN O O
fluorescently NN O O
labeled NN O O
platelets NN O O
was NN O O
observed NN O O
by NN O O
intravital NN O O
microscopy. NN O O
we NN O O

the NN O B-MSH:D006623
von NN B-Modifier I-MSH:D006623
Hippel-Lindau NN I-Modifier O
tumor NN I-Modifier O
suppressor NN O O
gene NN O O
is NN O O
required NN O O
for NN O O
cell NN O O
cycle NN O O
exit NN O O
upon NN O O
serum NN O O

the NN O B-MSH:D006623
inactivation NN O I-MSH:D006623
of NN O I-MSH:D006623
the NN O I-MSH:D006623
von NN B-Modifier I-MSH:D006623
Hippel-Lindau NN I-Modifier I-MSH:D006623
(VHL) NN I-Modifier B-MSH:D002292
tumor NN I-Modifier I-MSH:D002292
suppressor NN O I-MSH:D002292
gene NN O B-MSH:D002292
predisposes NN O B-MSH:D018325
affected NN O I-MSH:D018325
individuals NN O B-MSH:D002292
to NN O B-MSH:D006623
the NN O B-MSH:D009369
human NN O B-MSH:D006623
VHL NN B-SpecificDisease I-MSH:D002292
cancer NN I-SpecificDisease O
syndrome NN I-SpecificDisease O
and NN O O
is NN O O
associated NN O O
with NN O O
sporadic NN B-SpecificDisease O
renal NN I-SpecificDisease O
cell NN I-SpecificDisease O
carcinomas NN I-SpecificDisease O
( NN O O
RCC NN B-SpecificDisease O

both NN O B-MSH:D002292
vhl-positive NN O B-MSH:D006623
and NN O B-MSH:D006623
vhl-negative NN O B-MSH:D009369
RCC NN B-Modifier B-MSH:D006623
cells NN O O
exit NN O O
the NN O O
cell NN O O
cycle NN O O
by NN O O
contact NN O O
inhibition. NN O O
the NN O O
cyclin-dependent NN O O
kinase NN O O
inhibitor, NN O O
p NN O O
27, NN O O
accumulates NN O O
upon NN O O
serum NN O O
withdrawal, NN O O
only NN O O
in NN O O
the NN O O

nonsense NN O B-OMIM:613825
mutation NN O I-OMIM:613825
in NN O I-OMIM:613825
exon NN O O
4 NN O O

deficiency NN O B-MSH:D007153
of NN O I-MSH:D007153
the NN O B-OMIM:613825
ninth NN O I-OMIM:613825
component NN O B-OMIM:613825
of NN O B-MSH:D008585
human NN O I-MSH:D008585
complement NN O B-OMIM:613825
(c NN O O
9) NN O O
is NN O O
the NN O O
most NN O O
common NN O O
complement NN B-DiseaseClass O
deficiency NN I-DiseaseClass O
in NN O O
japan NN O O
but NN O O
is NN O O
rare NN O O
in NN O O
other NN O O
countries. NN O O
we NN O O
studied NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
C9 NN B-SpecificDisease O
deficiency NN I-SpecificDisease O
in NN O O
four NN O O
japanese NN O O
C9-deficient NN B-Modifier O
patients NN O O
who NN O O
had NN O O
suffered NN O O
from NN O O
meningococcal NN B-SpecificDisease O
meningitis NN I-SpecificDisease O
. NN O O
direct NN O O
sequencing NN O O
of NN O O
amplified NN O O
c NN O O
9 NN O O
cdna NN O O
and NN O O
dna NN O O
revealed NN O O
a NN O O

be NN O B-OMIM:613825
responsible NN O I-OMIM:613825
for NN O O
most NN O O

human NN O B-MSH:D006463
complement NN O I-MSH:D006463
factor NN O I-MSH:D006463
h NN O O
deficiency NN O O

this NN O B-OMIM:609814
study NN O I-OMIM:609814
reports NN O I-OMIM:609814
on NN O I-OMIM:609814
six NN O I-OMIM:609814
cases NN O I-OMIM:609814
of NN O I-OMIM:609814
deficiency NN B-SpecificDisease I-OMIM:609814
in NN I-SpecificDisease B-MSH:D007674
the NN I-SpecificDisease I-MSH:D007674
human NN I-SpecificDisease I-MSH:D007674
complement NN I-SpecificDisease B-MSH:D006463
regulatory NN I-SpecificDisease I-MSH:D006463
protein NN I-SpecificDisease I-MSH:D006463
Factor NN I-SpecificDisease B-MSH:D006463
H NN I-SpecificDisease O
(fh) NN O O
in NN O O
the NN O O
context NN O O
of NN O O
an NN O O
acute NN B-SpecificDisease O
renal NN I-SpecificDisease O
disease NN I-SpecificDisease O
. NN O O
five NN O O
of NN O O
the NN O O
cases NN O O
were NN O O
observed NN O O
in NN O O
children NN O O
presenting NN O O
with NN O O
idiopathic NN O O
hemolytic NN B-SpecificDisease O
uremic NN I-SpecificDisease O
syndrome NN I-SpecificDisease O
( NN O O
HUS NN B-SpecificDisease O
). NN O O
two NN O O
of NN O O
the NN O O
children NN O O
exhibited NN O O
a NN O O
homozygous NN O O
deficiency NN O O
characterized NN O O
by NN O O
the NN O O
absence NN O O
of NN O O
the NN O O
150-kd NN O O
form NN O O
of NN O O
factor NN O O
h NN O O
and NN O O
the NN O O
presence, NN O O
upon NN O O
immunoblotting, NN O O
of NN O O
the NN O O
42-kd NN O O
factor NN O O
h-like NN O O
protein NN O O
1 NN O O
(fhl-1) NN O O
and NN O O
other NN O O
fh-related NN O O
protein NN O O
(fhr) NN O O
bands. NN O O
southern NN O O
blot NN O O
and NN O O
pcr NN O O
analysis NN O O
of NN O O
dna NN O O
of NN O O

heterozygous NN O B-OMIM:609814
deficiency NN O I-OMIM:609814
and NN O I-OMIM:609814
exhibited NN O B-MSH:D007153
a NN O I-MSH:D007153
normal NN O B-MSH:D006463
immunoblotting NN O B-MSH:D006463
pattern NN O O
of NN O O

cell NN O O

germ-line NN O B-MSH:D061325
mutations NN O I-MSH:D061325
of NN O I-MSH:D061325
the NN O I-MSH:D061325
brca NN O B-MSH:D009369
1 NN O O
gene NN O O
predispose NN O O
women NN O O
to NN O O
early-onset NN O O
breast NN B-CompositeMention O
and NN I-CompositeMention O
ovarian NN I-CompositeMention O
cancer NN I-CompositeMention O
by NN O O
compromising NN O O
the NN O O
genes NN O O
presumptive NN O O
function NN O O
as NN O O
a NN O O
tumor NN B-Modifier O
suppressor. NN O O
although NN O O
the NN O O
biochemical NN O O
properties NN O O
of NN O O
brca NN O O
1 NN O O
polypeptides NN O O
are NN O O
not NN O O
understood, NN O O
their NN O O
expression NN O O
pattern NN O O
and NN O O
subcellular NN O O
localization NN O O
suggest NN O O
a NN O O
role NN O O
in NN O O
cell-cycle NN O O
regulation. NN O O
when NN O O
resting NN O O
cells NN O O
are NN O O
induced NN O O
to NN O O
proliferate, NN O O
the NN O O
steady-state NN O O
levels NN O O
of NN O O
brca NN O O
1 NN O O
increase NN O O
in NN O O
late NN O O
g NN O O
1 NN O O
and NN O O
reach NN O O
a NN O O
maximum NN O O
during NN O O
s NN O O
phase. NN O O
moreover, NN O O
in NN O O
s NN O O
phase NN O O
cells, NN O O
brca NN O O
1 NN O O
polypeptides NN O O
are NN O O
hyperphosphorylated NN O O
and NN O O
accumulate NN O O
into NN O O
discrete NN O O
subnuclear NN O O
foci NN O O
termed NN O O
" NN O O
brca NN O O
1 NN O O
nuclear NN O O
dots. NN O O
" NN O O
brca NN O O
1 NN O O
associates NN O O

those NN O B-MSH:D009369
of NN O O
brca NN O O
1, NN O O

genetic NN O B-MSH:C537182
basis NN O I-MSH:C537182
and NN O I-MSH:C537182
molecular NN O O
mechanism NN O O

ventricular NN O B-MSH:C537182
fibrillation NN O I-MSH:C537182
causes NN O I-MSH:C537182
more NN O B-MSH:C537182
than NN O B-MSH:C537182
300, NN O B-MSH:D003645
000 NN O I-MSH:D003645
sudden NN O B-MSH:C537182
deaths NN O B-MSH:C537182
each NN O O
year NN O O
in NN O O
the NN O O
usa NN O O
alone. NN O O
in NN O O
approximately NN O O
5-12% NN O O
of NN O O
these NN O O
cases, NN O O
there NN O O
are NN O O
no NN O O
demonstrable NN O O
cardiac NN O O
or NN O O
non-cardiac NN O O
causes NN O O
to NN O O
account NN O O
for NN O O
the NN O O
episode, NN O O
which NN O O
is NN O O
therefore NN O O
classified NN O O
as NN O O
idiopathic NN B-SpecificDisease O
ventricular NN I-SpecificDisease O
fibrillation NN I-SpecificDisease O
( NN O O

a NN O B-MSH:C537182
splice-donor NN O B-MSH:C537182
mutation, NN O O
and NN O O

prevalence NN O B-MSH:D011125
of NN O B-MSH:D015179
the NN O I-MSH:D015179
i NN O O
1307 NN O O

background NN O B-MSH:D015179
& NN O I-MSH:D015179
aims NN O B-MSH:D011125
israeli NN O I-MSH:D015179
jews NN O B-MSH:D015179
of NN O I-MSH:D015179
european NN O B-MSH:D009369
birth, NN O B-MSH:D015179
i. NN O I-MSH:D015179
e., NN O O
ashkenazim, NN O O
have NN O O

1307 NN O B-MSH:D009369
k NN O B-MSH:D009369
was NN O B-MSH:D015179
found NN O I-MSH:D015179
in NN O B-MSH:D009369
5. NN O B-MSH:D009369
0% NN O I-MSH:D009369
of NN O I-MSH:D009369
120 NN O I-MSH:D009369
european NN O B-MSH:D015179
and NN O I-MSH:D015179
1. NN O O
6% NN O O
of NN O O
188 NN O O
non-european NN O O

susceptibility NN O B-MSH:D013167
to NN O I-MSH:D013167
ankylosing NN B-SpecificDisease O
spondylitis NN I-SpecificDisease O
in NN O O
twins: NN O O
the NN O O
role NN O O
of NN O O
genes, NN O O
hla, NN O O
and NN O O

objective NN O B-MSH:D013167
to NN O B-MSH:D013167
determine NN O B-MSH:D013167
the NN O B-MSH:D012216
relative NN O I-MSH:D012216
effects NN O B-MSH:D013167
of NN O O
genetic NN O O
and NN O O
environmental NN O O
factors NN O O
in NN O O
susceptibility NN O O
to NN O O
ankylosing NN B-SpecificDisease O
spondylitis NN I-SpecificDisease O
( NN O O
AS NN B-SpecificDisease O
). NN O O
methods NN O O
twins NN O O
with NN O O

b NN O B-MSH:D013167
27-positive NN O O
dizygotic NN O O
(dz) NN O O
twin NN O O
pairs NN O O
(27%) NN O O
and NN O O
4 NN O O
of NN O O
32 NN O O
dz NN O O
twin NN O O
pairs NN O O
overall NN O O
(12. NN O O
5%). NN O O

hla-b NN O B-MSH:D013167
27 NN O O
accounts NN O O

the NN O B-MSH:D009369
apci NN O O
1307 NN O O
k NN O O
allele NN O O
and NN O O
cancer NN B-Modifier O
risk NN O O
in NN O O

mutations NN O B-MSH:D011125
in NN O I-MSH:D011125
apc NN O I-MSH:D011125
are NN O B-MSH:D011125
classically NN O B-MSH:D030342
associated NN O I-MSH:D030342
with NN O I-MSH:D030342
familial NN B-SpecificDisease B-MSH:D015179
adenomatous NN I-SpecificDisease I-MSH:D015179
polyposis NN I-SpecificDisease B-MSH:D015179
( NN O B-MSH:D009369
FAP NN B-SpecificDisease B-MSH:D015179
), NN O B-MSH:D009369
a NN O O
highly NN O O

we NN O B-MSH:D001943
genotyped NN O I-MSH:D001943
5, NN O I-MSH:D001943
081 NN O I-MSH:D001943
ashkenazi NN O I-MSH:D001943
volunteers NN O O
in NN O O
a NN O O
community NN O O
survey. NN O O
risk NN O O
of NN O O
developing NN O O
colorectal, NN B-CompositeMention O
breast NN I-CompositeMention O
and NN I-CompositeMention O
other NN I-CompositeMention O
cancers NN I-CompositeMention O
were NN O O

the NN O B-MSH:D006432
hemochromatosis NN B-Modifier O
gene NN O O
product NN O O
complexes NN O O
with NN O O
the NN O O
transferrin NN O O
receptor NN O O
and NN O O
lowers NN O O
its NN O O
affinity NN O O
for NN O O
ligand NN O O

we NN O B-MSH:D006432
recently NN O I-MSH:D006432
reported NN O O
the NN O O
positional NN O O
cloning NN O O
of NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
hereditary NN B-SpecificDisease O
hemochromatosis NN I-SpecificDisease O
called NN O O
hfe. NN O O
the NN O O
gene NN O O
product, NN O O
a NN O O
member NN O O
of NN O O
the NN O O
major NN O O
histocompatibility NN O O
complex NN O O
class NN O O
i-like NN O O
family, NN O O
was NN O O
found NN O O
to NN O O
have NN O O
a NN O O
mutation, NN O O
cys-282 NN O O
-- NN O O
> NN O O
tyr NN O O
(c NN O O
282 NN O O
y), NN O O
in NN O O
85% NN O O
of NN O O
patient NN O O
chromosomes. NN O O
this NN O O
mutation NN O O
eliminates NN O O
the NN O O
ability NN O O
of NN O O
hfe NN O O
to NN O O
associate NN O O
with NN O O
beta NN O O
2-microglobulin NN O O
(beta NN O O
2 NN O O
m) NN O O
and NN O O
prevents NN O O
cell-surface NN O O
expression. NN O O
a NN O O
second NN O O
mutation NN O O
that NN O O
has NN O O
no NN O O
effect NN O O
on NN O O
beta NN O O
2 NN O O
m NN O O
association, NN O O
h NN O O
63 NN O O
d, NN O O
was NN O O
found NN O O
in NN O O
eight NN O O
out NN O O
of NN O O
nine NN O O
patients NN O O
heterozygous NN O O
for NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
mutant. NN O O
in NN O O
this NN O O
report, NN O O
we NN O O
demonstrate NN O O
in NN O O
cultured NN O O

wild-type NN O O
and NN O O
h NN O O
63 NN O O
d NN O O
hfe NN O O
proteins NN O O
form NN O O
stable NN O O
complexes NN O O
with NN O O
the NN O O
transferrin NN O O
receptor NN O O
(tfr). NN O O
the NN O O
c NN O O
282 NN O O
y NN O O
mutation NN O O
nearly NN O O
completely NN O O
prevents NN O O
the NN O O
association NN O O
of NN O O
the NN O O
mutant NN O O
hfe NN O O
protein NN O O
with NN O O
the NN O O
tfr. NN O O
studies NN O O
on NN O O
cell-associated NN O O
transferrin NN O O
at NN O O
37 NN O O
degrees NN O O
c NN O O
suggest NN O O
that NN O O
the NN O O
overexpressed NN O O
wild-type NN O O
hfe NN O O
protein NN O O
decreases NN O O
the NN O O
affinity NN O O
of NN O O
the NN O O
tfr NN O O
for NN O O
transferrin. NN O O
the NN O O
overexpressed NN O O
h NN O O
63 NN O O
d NN O O
protein NN O O
does NN O O
not NN O O
have NN O O
this NN O O
effect, NN O O
providing NN O O
the NN O O
first NN O O
direct NN O O
evidence NN O O
for NN O O
a NN O O
functional NN O O
consequence NN O O
of NN O O
the NN O O
h NN O O
63 NN O O
d NN O O
mutation. NN O O
addition NN O O
of NN O O
soluble NN O O
wild-type NN O O
hfe/beta NN O O
2 NN O O
m NN O O
heterodimers NN O O
to NN O O
cultured NN O O
cells NN O O
also NN O O
decreased NN O O
the NN O O
apparent NN O O
affinity NN O O
of NN O O
the NN O O
tfr NN O O
for NN O O
its NN O O
ligand NN O O

degrees NN O B-MSH:D006432
c, NN O I-MSH:D006432
the NN O O
added NN O O

cycloheximide NN O B-MSH:D016109
facilitates NN O I-MSH:D016109
the NN O I-MSH:D016109
identification NN O I-MSH:D016109
of NN O O
aberrant NN O O

patients NN O B-MSH:D016109
with NN O I-MSH:D016109
generalized NN O I-MSH:D016109
atrophic NN B-SpecificDisease B-MSH:D016109
benign NN I-SpecificDisease I-MSH:D016109
epidermolysis NN I-SpecificDisease I-MSH:D016109
bullosa NN I-SpecificDisease I-MSH:D016109
often NN O O
show NN O O
decreased NN O O
expression NN O O
of NN O O
type NN O O
xvii NN O O
collagen, NN O O
a NN O O
transmembrane NN O O
hemidesmosomal NN O O
protein NN O O
encoded NN O O
by NN O O
col NN O O
17 NN O O
a NN O O
1. NN O O
this NN O O
report NN O O
documents NN O O
a NN O O
novel NN O O
splice-site NN O O
mutation NN O O
in NN O O
col NN O O
17 NN O O
a NN O O
1 NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
generalized NN O O
atrophic NN B-SpecificDisease O
benign NN I-SpecificDisease O
epidermolysis NN I-SpecificDisease O
bullosa NN I-SpecificDisease O
, NN O O
and NN O O
applies NN O O
a NN O O
new NN O O
methodology NN O O
to NN O O
define NN O O
and NN O O
characterize NN O O
the NN O O
resulting NN O O
mrna NN O O
splice NN O O
variants. NN O O
mutational NN O O
analysis NN O O
of NN O O
col NN O O
17 NN O O
a NN O O
1 NN O O
identified NN O O
a NN O O
maternally NN O O
inherited NN O O
g-to-t NN O O
transversion NN O O
at NN O O
the NN O O
-1 NN O O
position NN O O
of NN O O
exon NN O O
32. NN O O
this NN O O
acceptor NN O O

mutation NN O O
on NN O O
splicing NN O O
of NN O O
col NN O O
17 NN O O
a NN O O
1 NN O O
transcripts NN O O
were NN O O
determined NN O O
using NN O O
reverse NN O O
transcriptase NN O O
polymerase NN O O
chain NN O O
reaction NN O O
of NN O O
total NN O O
rna NN O O
from NN O O
keratinocytes NN O O
incubated NN O O
for NN O O
2. NN O O
5 NN O O
h NN O O
in NN O O
the NN O O
presence NN O O
or NN O O
absence NN O O
of NN O O
10 NN O O
microg NN O O
cycloheximide NN O O
per NN O O
ml. NN O O
using NN O O
this NN O O
approach, NN O O
an NN O O
abnormally NN O O
spliced NN O O
transcript NN O O
was NN O O
identified NN O O
that NN O O
contains NN O O
an NN O O
extra NN O O
264 NN O O
bases NN O O
upstream NN O O
from NN O O
exon NN O O
32, NN O O
resulting NN O O
in NN O O
a NN O O
premature NN O O
termination NN O O
codon NN O O
27 NN O O
bp NN O O
downstream NN O O
from NN O O
the NN O O
cryptic NN O O
splice NN O O
site. NN O O
three NN O O
other NN O O
splice NN O O
variants, NN O O
including NN O O
one NN O O
derived NN O O

at NN O O

the NN O B-MSH:D009223
dmpk NN O I-MSH:D009223
gene NN O O
of NN O O
severely NN O O
affected NN O O
myotonic NN B-Modifier O
dystrophy NN I-Modifier O
patients NN O O
is NN O O
hypermethylated NN O O
proximal NN O O

using NN O B-MSH:D009223
methylation-sensitive NN O I-MSH:D009223
restriction NN O O
enzymes, NN O O
we NN O O
characterized NN O O
the NN O O
methylation NN O O
pattern NN O O
on NN O O
the NN O O
5 NN O O
side NN O O
of NN O O
the NN O O
ctg NN O O
repeat NN O O
in NN O O
the NN O O
dmpk NN O O
gene NN O O
of NN O O
normal NN O O
individuals NN O O
and NN O O
of NN O O
patients NN O O
affected NN O O
with NN O O
myotonic NN B-SpecificDisease O
dystrophy NN I-SpecificDisease O
, NN O O
showing NN O O
expansions NN O O
of NN O O
the NN O O
repetitive NN O O
sequence. NN O O
the NN O O
gene NN O O
segment NN O O
analyzed NN O O
corresponds NN O O
to NN O O
the NN O O
genomic NN O O
saci-hindiii NN O O
fragment NN O O
carrying NN O O
exons NN O O
11-15. NN O O
there NN O O
is NN O O
constitutive NN O O
methylation NN O O
in NN O O
intron NN O O
12 NN O O
at NN O O
restriction NN O O
sites NN O O
of NN O O
sacii NN O O
and NN O O
hhai, NN O O
localized NN O O
1, NN O O
159-1, NN O O
232 NN O O
bp NN O O
upstream NN O O
of NN O O
the NN O O
ctg NN O O
repeat, NN O O
whereas NN O O
most, NN O O
if NN O O
not NN O O
all, NN O O
of NN O O
the NN O O
other NN O O
sites NN O O
of NN O O
sacii, NN O O
hhai, NN O O
and NN O O

sites NN O O
was NN O O
found NN O O
in NN O O
the NN O O
mutated NN O O
allele. NN O O
in NN O O
most NN O O
of NN O O
these NN O O
patients, NN O O
the NN O O
onset NN O O
of NN O O
the NN O O
disease NN O O
was NN O O
congenital. NN O O
preliminary NN O O
in NN O O
vivo NN O O
footprinting NN O O
data NN O O
gave NN O O

progression NN O B-MSH:D009223
of NN O I-MSH:D009223
somatic NN O O
ctg NN O O
repeat NN O O

the NN O B-MSH:D009223
genetic NN O I-MSH:D009223
basis NN O B-MSH:D009223
of NN O B-MSH:D009223
myotonic NN B-SpecificDisease O
dystrophy NN I-SpecificDisease O
( NN O O
DM NN B-SpecificDisease O
) NN O O
is NN O O
the NN O O
expansion NN O O
of NN O O
an NN O O
unstable NN O O
ctg NN O O
repeat NN O O
in NN O O
the NN O O
34 NN O O
utr NN O O
of NN O O
the NN O O
DM NN B-Modifier O
protein NN O O
kinase NN O O
gene NN O O
on NN O O
chromosome NN O O
19. NN O O
one NN O O
of NN O O
the NN O O
principal NN O O
features NN O O
of NN O O
the NN O O
DM NN B-Modifier O
mutation NN O O
is NN O O
an NN O O
extraordinarily NN O O
high NN O O
level NN O O
of NN O O
somatic NN O O
mosaicism, NN O O
due NN O O
to NN O O
an NN O O
extremely NN O O
high NN O O
degree NN O O
of NN O O
somatic NN O O
instability NN O O
both NN O O
within NN O O
and NN O O
between NN O O
different NN O O
tissues. NN O O
this NN O O
instability NN O O
appears NN O O
to NN O O
be NN O O
biased NN O O
towards NN O O
further NN O O
expansion NN O O
and NN O O
continuous NN O O
throughout NN O O
the NN O O
life NN O O
of NN O O
an NN O O
individual, NN O O
features NN O O
that NN O O
could NN O O
be NN O O
associated NN O O
with NN O O
the NN O O
progressive NN O O
nature NN O O
of NN O O
the NN O O
disease. NN O O
although NN O O
increasing NN O O
measured NN O O
allele NN O O
size NN O O

order NN O B-MSH:D009223
to NN O B-MSH:D009223
further NN O I-MSH:D009223
characterize NN O O
the NN O O
dynamics NN O O
of NN O O
DM NN B-Modifier O
ctg NN O O
repeat NN O O
somatic NN O O
instability, NN O O
we NN O O
have NN O O
studied NN O O
repeat NN O O
length NN O O
changes NN O O
over NN O O
time NN O O
in NN O O
111 NN O O
myotonic NN B-Modifier O
dystrophy NN I-Modifier O
patients NN O O
with NN O O
varying NN O O
clinical NN O O
severity NN O O
and NN O O
ctg NN O O
repeat NN O O
size NN O O
over NN O O
time NN O O
intervals NN O O
of NN O O
1-7 NN O O
years. NN O O
we NN O O
have NN O O
found NN O O
a NN O O
direct NN O O
progression NN O O
of NN O O
the NN O O
size NN O O
heterogeneity NN O O
over NN O O
time NN O O
related NN O O
to NN O O
initial NN O O
ctg NN O O
repeat NN O O
size NN O O
and NN O O
the NN O O
time NN O O
interval NN O O
and NN O O
always NN O O
biased NN O O
towards NN O O
further NN O O
expansion. NN O O
attempts NN O O
to NN O O
mathematically NN O O

inherited NN O B-MSH:D009369
colorectal NN O O
polyposis NN O O
and NN O O
cancer NN B-Modifier O
risk NN O O
of NN O O
the NN O O
apc NN O O

germ-line NN O B-MSH:D011125
and NN O B-MSH:D015179
somatic NN O I-MSH:D015179
truncating NN O B-MSH:D011125
mutations NN O I-MSH:D011125
of NN O I-MSH:D011125
the NN O I-MSH:D011125
APC NN B-Modifier B-MSH:D011125
gene NN O I-MSH:D018256
are NN O B-MSH:D015179
thought NN O I-MSH:D015179
to NN O O
initiate NN O O
colorectal NN B-Modifier O
tumor NN I-Modifier O
formation NN O O
in NN O O
familial NN B-SpecificDisease O
adenomatous NN I-SpecificDisease O
polyposis NN I-SpecificDisease O
syndrome NN I-SpecificDisease O
and NN O O
sporadic NN O O
colorectal NN O O
carcinogenesis, NN O O
respectively. NN O O
recently, NN O O
an NN O O
isoleucine-- NN O O
> NN O O
lysine NN O O
polymorphism NN O O
at NN O O
codon NN O O
1307 NN O O
(i NN O O
1307 NN O O
k) NN O O
of NN O O
the NN O O
APC NN B-Modifier O

apc NN O B-MSH:D015179
i NN O I-MSH:D015179
1307 NN O B-MSH:D000236
k NN O B-MSH:D015179
allele NN O I-MSH:D015179
is NN O B-MSH:D000236
associated NN O B-MSH:D015179
with NN O I-MSH:D015179
an NN O B-MSH:D015179
estimated NN O I-MSH:D015179
relative NN O O

prevention NN O O

human NN O B-MSH:D019337
mlh NN O I-MSH:D019337
1 NN O B-MSH:D009456
deficiency NN O I-MSH:D009456
predisposes NN O I-MSH:D009456
to NN O O

heterozygous NN O B-MSH:D003123
germ-line NN O I-MSH:D003123
mutations NN O I-MSH:D003123
in NN O I-MSH:D003123
the NN O B-MSH:D003123
dna NN O I-MSH:D003123
mismatch NN O I-MSH:D003123
repair NN O I-MSH:D003123
genes NN O B-MSH:D019337
lead NN O I-MSH:D019337
to NN O B-MSH:D009456
hereditary NN B-SpecificDisease I-MSH:D009456
nonpolyposis NN I-SpecificDisease B-MSH:D009456
colorectal NN I-SpecificDisease B-MSH:D007938
cancer NN I-SpecificDisease B-MSH:D008223
. NN O B-MSH:D009456
the NN O I-MSH:D009456
disease NN O I-MSH:D009456
susceptibility NN O O
of NN O O

are NN O B-MSH:D003072
dp NN O I-MSH:D003072
71 NN O B-MSH:D020388
and NN O I-MSH:D020388
dp NN O I-MSH:D020388
140 NN O B-MSH:D020388
brain NN O I-MSH:D020388
dystrophin NN O I-MSH:D020388
isoforms NN O B-MSH:D020388
related NN O B-MSH:D003072
to NN O I-MSH:D003072
cognitive NN B-DiseaseClass B-MSH:D020388
impairment NN I-DiseaseClass O
in NN O O
Duchenne NN B-SpecificDisease O
muscular NN I-SpecificDisease O
dystrophy NN I-SpecificDisease O
? NN O O
molecular NN O O
study NN O O
and NN O O
neuropsychological NN O O
analysis NN O O
were NN O O
performed NN O O
concurrently NN O O
on NN O O
49 NN O O
patients NN O O
with NN O O
Duchenne NN B-SpecificDisease O
muscular NN I-SpecificDisease O
dystrophy NN I-SpecificDisease O
( NN O O
DMD NN B-SpecificDisease O
) NN O O
in NN O O
order NN O O
to NN O O
find NN O O
a NN O O
molecular NN O O
explanation NN O O
for NN O O
the NN O O
cognitive NN B-DiseaseClass O
impairment NN I-DiseaseClass O
observed NN O O
in NN O O
most NN O O
DMD NN B-Modifier O
patients. NN O O
complete NN O O
analysis NN O O
of NN O O
the NN O O
dystrophin NN O O
gene NN O O
was NN O O
performed NN O O
to NN O O
define NN O O
the NN O O
localization NN O O
of NN O O
deletions NN O O

with NN O B-MSH:D003072
cognitive NN B-DiseaseClass B-MSH:D001927
impairment NN I-DiseaseClass I-MSH:D001927
. NN O B-MSH:D020388
two NN O B-MSH:D003072
altered NN O I-MSH:D003072
dp NN O B-MSH:D020388
71 NN O O
transcripts NN O O

a NN O B-MSH:D001714
genome-wide NN O I-MSH:D001714
search NN O I-MSH:D001714
for NN O O
chromosomal NN O O
loci NN O O
linked NN O O
to NN O O
mental NN O O
health NN O O

bipolar NN O B-MSH:D001714
affective NN O B-MSH:D001714
disorder NN O I-MSH:D001714
( NN O B-MSH:D001714
BPAD NN B-SpecificDisease B-MSH:D019964
; NN O B-MSH:D003866
manic-depressive NN B-SpecificDisease B-MSH:D001714
illness NN I-SpecificDisease B-MSH:D001714
) NN O B-MSH:D030342
is NN O I-MSH:D030342
characterized NN O B-MSH:D001523
by NN O I-MSH:D001523
episodes NN O B-MSH:D001714
of NN O O
mania NN B-SpecificDisease O
and/or NN O O
hypomania NN B-SpecificDisease O
interspersed NN O O
with NN O O
periods NN O O

chromosome NN O B-MSH:D001714
4 NN O B-MSH:D019964
p NN O I-MSH:D019964
at NN O O
d NN O O

hereditary NN O O

the NN O B-OMIM:609536
first NN O I-OMIM:609536
recognized NN O I-OMIM:609536
human NN O I-OMIM:609536
kindred NN O I-OMIM:609536
with NN O I-OMIM:609536
hereditary NN B-SpecificDisease I-OMIM:609536
deficiency NN I-SpecificDisease B-MSH:D008180
of NN I-SpecificDisease I-MSH:D008180
the NN I-SpecificDisease I-MSH:D008180
fifth NN I-SpecificDisease O
component NN I-SpecificDisease O
of NN I-SpecificDisease O
complement NN I-SpecificDisease O
(c NN O O
5) NN O O
is NN O O
described. NN O O
the NN O O
proband, NN O O
a NN O O
20-year-old NN O O
black NN O O
female NN O O
with NN O O
systemic NN B-SpecificDisease O
lupus NN I-SpecificDisease O
erythematosus NN I-SpecificDisease O
since NN O O
age NN O O
11, NN O O
lacked NN O O
serum NN O O
hemolytic NN O O
complement NN O O
activity, NN O O
even NN O O
during NN O O
remission. NN O O
c NN O O
5 NN O O
was NN O O
undetectable NN O O
in NN O O
her NN O O
serum NN O O
by NN O O
both NN O O
immunodiffusion NN O O
and NN O O
hemolytic NN O O
assays. NN O O
other NN O O
complement NN O O
components NN O O
were NN O O
normal NN O O
during NN O O
remission NN O O
of NN O O
lupus, NN O O
but NN O O
c NN O O
1, NN O O
c NN O O
4, NN O O
c NN O O
2, NN O O
and NN O O
c NN O O
3 NN O O
levels NN O O
fell NN O O
during NN O O
exacerbations. NN O O
a NN O O
younger NN O O
half-sister, NN O O
who NN O O
had NN O O
no NN O O
underlying NN O O
disease, NN O O
was NN O O
also NN O O
found NN O O
to NN O O
lack NN O O
immunochemically NN O O
detectable NN O O
c NN O O
5. NN O O
by NN O O
hemolytic NN O O

5 NN O B-OMIM:609536
levels NN O I-OMIM:609536
of NN O B-OMIM:609536
other NN O B-OMIM:609536
family NN O B-OMIM:609536
members NN O B-OMIM:609536
were NN O O
either NN O O
normal NN O O
or NN O O
approximately NN O O
half-normal, NN O O
consistent NN O O
with NN O O
autosomal NN O O
codominant NN O O
inheritance NN O O
of NN O O
the NN O O
gene NN O O
determining NN O O
C5 NN B-SpecificDisease O
deficiency NN I-SpecificDisease O
. NN O O
normal NN O O
hemolytic NN O O
titers NN O O
were NN O O
restored NN O O

5 NN O B-MSH:D005921
inhibitor NN O B-MSH:D014657
or NN O B-MSH:D001168
inactivator. NN O B-MSH:D001424
of NN O I-MSH:D001424
clinical NN O B-OMIM:609536
interest NN O B-MSH:D007239
are NN O I-MSH:D007239
(a) NN O O
the NN O O

detection NN O B-MSH:D001260
of NN O O
heterozygous NN O O
carriers NN O O
of NN O O
the NN O O
ataxia-telangiectasia NN B-Modifier O
(atm) NN O O
gene NN O O
by NN O O
g NN O O
2 NN O O
phase NN O O

in NN O B-MSH:D001260
ataxia-telangiectasia NN B-Modifier B-MSH:D030342
( NN O I-MSH:D030342
A-T NN B-Modifier B-MSH:D009369
) NN O B-MSH:D001260
patients, NN O B-MSH:D009369
mutations NN O B-MSH:D001260
in NN O B-MSH:D001260
a NN O B-MSH:D001260
single NN O O
gene, NN O O
atm, NN O O
result NN O O
in NN O O
an NN O O

significantly NN O B-MSH:D001260
increased NN O B-MSH:D009369
levels NN O I-MSH:D009369
of NN O I-MSH:D009369
radiation-induced NN O I-MSH:D009369
chromatid NN O B-MSH:D009369
damage NN O O
relative NN O O
to NN O O
that NN O O
of NN O O

the NN O B-OMIM:612446
molecular NN O I-OMIM:612446
basis NN O O
of NN O O
C6 NN B-SpecificDisease O
deficiency NN I-SpecificDisease O
in NN O O
the NN O O

deficiency NN O B-MSH:D008589
of NN O I-MSH:D008589
the NN O B-OMIM:612446
sixth NN O I-OMIM:612446
component NN O O
of NN O O
human NN O O
complement NN O O
(c NN O O
6) NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
a NN O O
number NN O O
of NN O O
families NN O O
from NN O O
the NN O O
western NN O O
cape, NN O O
south NN O O
africa. NN O O
Meningococcal NN B-SpecificDisease O
disease NN I-SpecificDisease O
is NN O O
endemic NN O O
in NN O O
the NN O O
cape NN O O
and NN O O
almost NN O O
all NN O O
pedigrees NN O O
of NN O O
total NN O O
C6 NN B-SpecificDisease O
deficiency NN I-SpecificDisease O
(c NN O O
6 NN O O
q NN O O
0) NN O O
have NN O O
been NN O O
ascertained NN O O
because NN O O
of NN O O
recurrent NN O O
disease. NN O O
we NN O O
have NN O O
sequenced NN O O
the NN O O
expressed NN O O
exons NN O O
of NN O O
the NN O O
c NN O O
6 NN O O
gene NN O O
from NN O O
selected NN O O
cases NN O O
and NN O O
have NN O O
found NN O O
three NN O O
molecular NN O O
defects NN O O
leading NN O O
to NN O O
total NN O O
deficiency NN O O
879 NN O O
delg, NN O O
which NN O O
is NN O O
the NN O O
common NN O O
defect NN O O
in NN O O
the NN O O
cape NN O O
and NN O O
hitherto NN O O

small NN O B-OMIM:612446
variations NN O O
were NN O O
observed. NN O O
the NN O O
1936 NN O O
delg NN O O
defect NN O O
was NN O O
observed NN O O
only NN O O
once NN O O
in NN O O
the NN O O
cape, NN O O
but NN O O
its NN O O
associated NN O O
haplotype NN O O

the NN O B-MSH:D007966
r NN O I-MSH:D007966
496 NN O O
h NN O O

deficiency NN O B-MSH:D007966
of NN O I-MSH:D007966
arylsulfatase NN O B-MSH:D007966
a NN O B-MSH:D007966
(arsa) NN O B-MSH:D007966
enzyme NN O B-MSH:D007966
activity NN O O

piebaldism NN O B-MSH:D003638
with NN O O
deafness NN B-SpecificDisease O
: NN O O
molecular NN O O
evidence NN O O
for NN O O
an NN O O

in NN O B-MSH:D016116
a NN O B-MSH:D006319
south NN O I-MSH:D006319
african NN O B-MSH:D001304
girl NN O I-MSH:D001304
of NN O B-MSH:D003638
xhosa NN O B-MSH:D016116
stock NN O B-MSH:D006319
with NN O I-MSH:D006319
severe NN O B-MSH:D016116
piebaldism NN B-SpecificDisease B-MSH:D014849
and NN O O
profound NN O O

genetic NN O B-MSH:D001943
heterogeneity NN O I-MSH:D001943
and NN O B-MSH:D001943
penetrance NN O I-MSH:D001943
analysis NN O O
of NN O O
the NN O O
brca NN O O

the NN O B-MSH:D001943
contribution NN O I-MSH:D001943
of NN O I-MSH:D001943
brca NN O B-MSH:D001943
1 NN O I-MSH:D001943
and NN O B-MSH:D001943
brca NN O I-MSH:D001943
2 NN O B-MSH:D010051
to NN O I-MSH:D010051
inherited NN B-SpecificDisease I-MSH:D010051
breast NN I-SpecificDisease B-MSH:D061325
cancer NN I-SpecificDisease I-MSH:D061325
was NN O O
assessed NN O O
by NN O O
linkage NN O O
and NN O O
mutation NN O O
analysis NN O O
in NN O O
237 NN O O
families, NN O O
each NN O O
with NN O O
at NN O O
least NN O O
four NN O O
cases NN O O

the NN O B-MSH:D018567
majority NN O I-MSH:D018567
of NN O I-MSH:D018567
families NN O I-MSH:D018567
with NN O I-MSH:D018567
male NN B-CompositeMention I-MSH:D001943
and NN I-CompositeMention O
female NN I-CompositeMention O
breast NN I-CompositeMention O
cancer NN I-CompositeMention O
were NN O O
due NN O O
to NN O O
brca NN O O
2 NN O O
(76%). NN O O
the NN O O
largest NN O O
proportion NN O O
(67%) NN O O
of NN O O
families NN O O
due NN O O
to NN O O
other NN O O
genes NN O O
was NN O O
found NN O O
in NN O O
families NN O O
with NN O O
four NN O O
or NN O O
five NN O O
cases NN O O
of NN O O
female NN O O
breast NN B-SpecificDisease O
cancer NN I-SpecificDisease O
only. NN O O
these NN O O
estimates NN O O
were NN O O
not NN O O
substantially NN O O
affected NN O O
either NN O O
by NN O O
changing NN O O
the NN O O
assumed NN O O
penetrance NN O O
model NN O O
for NN O O
brca NN O O
1 NN O O
or NN O O
by NN O O
including NN O O
or NN O O
excluding NN O O
brca NN O O
1 NN O O
mutation NN O O
data. NN O O
among NN O O
those NN O O
families NN O O
with NN O O
disease NN O O
due NN O O
to NN O O
brca NN O O
1 NN O O
that NN O O
were NN O O
tested NN O O
by NN O O
one NN O O
of NN O O
the NN O O
standard NN O O
screening NN O O
methods, NN O O
mutations NN O O
were NN O O
detected NN O O

maximizing NN O B-MSH:D001943
the NN O I-MSH:D001943
lod NN O B-MSH:D010051
score NN O I-MSH:D010051
in NN O B-MSH:D001943
brca NN O I-MSH:D001943
2-mutation NN O O
families, NN O O
over NN O O
all NN O O
possible NN O O
penetrance NN O O
functions. NN O O
the NN O O
estimated NN O O
cumulative NN O O
risk NN O O
of NN O O
breast NN B-SpecificDisease O
cancer NN I-SpecificDisease O
reached NN O O
28% NN O O
(95% NN O O
ci NN O O
9% NN O O
-44%) NN O O
by NN O O
age NN O O
50 NN O O
years NN O O
and NN O O
84% NN O O
(95% NN O O

severe NN O B-MSH:D009765
early-onset NN O B-MSH:D000309
obesity NN B-SpecificDisease O
, NN O O
adrenal NN B-DiseaseClass O
insufficiency NN I-DiseaseClass O
and NN O O
red NN O O
hair NN O O
pigmentation NN O O
caused NN O O
by NN O O

sequential NN O B-OMIM:201400
cleavage NN O I-OMIM:201400
of NN O B-MSH:D009765
the NN O O
precursor NN O O
protein NN O O
pre-pro-opiomelanocortin NN O O
(pomc) NN O O
generates NN O O
the NN O O
melanocortin NN O O
peptides NN O O
adrenocorticotrophin NN O O
(acth), NN O O
melanocyte-stimulating NN O O
hormones NN O O
(msh) NN O O
alpha, NN O O
beta NN O O
and NN O O
gamma NN O O
as NN O O
well NN O O
as NN O O

with NN O B-MSH:D009765
human NN O B-MSH:D009765
obesity NN B-SpecificDisease I-OMIM:201400
. NN O B-MSH:D030342
the NN O I-MSH:D030342
dual NN O B-MSH:D004700
role NN O I-MSH:D004700
of NN O I-MSH:D004700
alpha-msh NN O O
in NN O O
regulating NN O O
food NN O O
intake NN O O

-onset NN O B-MSH:D009765
obesity NN B-SpecificDisease I-MSH:D000309
, NN O O
adrenal NN B-DiseaseClass O
insufficiency NN I-DiseaseClass O
and NN O O

the NN O B-MSH:D009369
tumor NN B-Modifier O
suppressor NN O O
gene NN O O
smad NN O O
4/dpc NN O O
4 NN O O
is NN O O
required NN O O
for NN O O
gastrulation NN O O
and NN O O
later NN O O
for NN O O
anterior NN O O
development NN O O
of NN O O
the NN O O
mouse NN O O

mutations NN O B-MSH:D009369
in NN O B-MSH:D010190
the NN O I-MSH:D010190
smad NN O B-MSH:D005317
4/dpc NN O I-MSH:D005317
4 NN O B-MSH:D004194
tumor NN B-Modifier B-MSH:D004194
suppressor NN O O
gene, NN O O
a NN O O
key NN O O
signal NN O O
transducer NN O O
in NN O O
most NN O O
tgfbeta-related NN O O
pathways, NN O O
are NN O O
involved NN O O
in NN O O

severe NN O O

coincidence NN O B-MSH:D007966
of NN O I-MSH:D007966
two NN O O
novel NN O O
arylsulfatase NN O O
a NN O O
alleles NN O O
and NN O O
mutation NN O O

in NN O B-MSH:D007966
a NN O I-MSH:D007966
family NN O B-MSH:D007966
with NN O B-MSH:D007966
three NN O O
siblings, NN O O
one NN O O
developed NN O O
classical NN O O
late NN O O
infantile NN O O
metachromatic NN B-SpecificDisease O
leukodystrophy NN I-SpecificDisease O
( NN O O
MLD NN B-SpecificDisease O
), NN O O
fatal NN O O
at NN O O
age NN O O
5 NN O O
years, NN O O
with NN O O
deficient NN O O
arylsulfatase NN O O
a NN O O
(arsa) NN O O
activity NN O O
and NN O O
increased NN O O
galactosylsulfatide NN O O
(gs) NN O O
excretion. NN O O
the NN O O
two NN O O
other NN O O
siblings, NN O O
apparently NN O O
healthy NN O O
at NN O O
12 NN O O
(1/2) NN O O
and NN O O
15 NN O O
years, NN O O
respectively, NN O O
and NN O O
their NN O O
father, NN O O
apparently NN O O
healthy NN O O
as NN O O
well, NN O O
presented NN O O
arsa NN O O
and NN O O
gs NN O O
values NN O O
within NN O O
the NN O O

exon NN O B-MSH:D007966
1 NN O B-MSH:D007966
(7 NN O B-MSH:D007966
delg). NN O O
the NN O O
two NN O O
clinically NN O O
unaffected NN O O
siblings NN O O
carried NN O O
the NN O O
maternal NN O O
mutation NN O O
459 NN O O
+ NN O O
1 NN O O
g NN O O
> NN O O
a NN O O
and, NN O O

diagnostic NN O O

low NN O O

appreciable NN O B-MSH:D008545
beta NN O B-MSH:D013661
hexosaminidase NN O I-MSH:D013661
a NN O I-MSH:D013661
(hex NN O I-MSH:D013661
a) NN O B-MSH:D013661
activity NN O I-MSH:D013661
has NN O B-MSH:D013661
been NN O B-MSH:D013661
detected NN O O
in NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
and NN O O
melanoma NN B-Modifier O
tissue NN O O
from NN O O
healthy NN O O
individuals NN O O
previously NN O O
reported NN O O
as NN O O
having NN O O
deficiency NN B-SpecificDisease O
of NN I-SpecificDisease O
hex NN I-SpecificDisease O
A NN I-SpecificDisease O
activity NN O O
indistinguishable NN O O
from NN O O
that NN O O
of NN O O
patients NN O O

the NN O B-MSH:D013661
rare NN O B-MSH:D013661
mutant NN O B-MSH:D013661
may NN O I-MSH:D013661
be NN O I-MSH:D013661
indistinguishable NN O O
from NN O O
heterozygotes NN O O
for NN O O
the NN O O
common NN O O
TSD NN B-Modifier O
mutant. NN O O
however, NN O O

a NN O B-MSH:D011218
mouse NN O I-MSH:D011218
model NN O O
for NN O O
Prader-Willi NN B-SpecificDisease O

imprinting NN O B-MSH:D011218
in NN O I-MSH:D011218
the NN O B-MSH:D011218
15 NN O B-MSH:D011218
q NN O B-MSH:D011218
11-q NN O B-MSH:D011218
13 NN O O
region NN O O
involves NN O O
an NN O O
imprinting NN O O
centre NN O O
(ic), NN O O
mapping NN O O

the NN O O

a NN O B-MSH:D016109
deletion NN O I-MSH:D016109
mutation NN O I-MSH:D016109
in NN O I-MSH:D016109
col NN O O
17 NN O O
a NN O O
1 NN O O
in NN O O
five NN O O
austrian NN O O
families NN O O

patients NN O B-MSH:D016109
with NN O I-MSH:D016109
generalized NN O I-MSH:D016109
atrophic NN B-SpecificDisease B-MSH:D016109
benign NN I-SpecificDisease I-MSH:D016109
epidermolysis NN I-SpecificDisease I-MSH:D016109
bullosa NN I-SpecificDisease B-MSH:D001768
, NN O B-MSH:C538333
a NN O I-MSH:C538333
usually NN O B-MSH:C531609
nonlethal NN O I-MSH:C531609
form NN O B-MSH:D014071
of NN O I-MSH:D014071
junctional NN B-SpecificDisease I-MSH:C536183
epidermolysis NN I-SpecificDisease B-MSH:D016109
bullosa NN I-SpecificDisease I-MSH:D016109
, NN O I-MSH:D016109
have NN O I-MSH:D016109
generalized NN O O
blistering NN B-SpecificDisease O
, NN O O
nail NN B-SpecificDisease O
dystrophy NN I-SpecificDisease O
, NN O O
patchy NN B-SpecificDisease O
alopecia NN I-SpecificDisease O
, NN O O
and NN O O
dental NN B-DiseaseClass O
abnormalities NN I-DiseaseClass O
. NN O O
Skin NN B-DiseaseClass O
fragility NN I-DiseaseClass O
in NN O O
most NN O O
cases NN O O
is NN O O
due NN O O
to NN O O
mutations NN O O
in NN O O
the NN O O
gene NN O O
encoding NN O O
type NN O O
xvii NN O O
collagen NN O O
(col NN O O
17 NN O O
a NN O O
1). NN O O
recently, NN O O
we NN O O
reported NN O O
five NN O O
austrian NN O O
families NN O O
with NN O O
generalized NN O O
atrophic NN B-SpecificDisease O
benign NN I-SpecificDisease O
epidermolysis NN I-SpecificDisease O
bullosa NN I-SpecificDisease O
who NN O O
share NN O O
the NN O O
same NN O O
col NN O O
17 NN O O
a NN O O
1 NN O O
mutation. NN O O
affected NN O O
individuals NN O O
in NN O O
three NN O O
families NN O O
are NN O O
homozygous NN O O
for NN O O

based NN O O
on NN O O
their NN O O
informativeness. NN O O
one NN O O
of NN O O
these, NN O O
not NN O O
previously NN O O
reported, NN O O
was NN O O
2988 NN O O
a NN O O
or NN O O
c NN O O
that NN O O
introduces NN O O
a NN O O
new NN O O
restriction NN O O
site NN O O
for NN O O
eco NN O O
0109 NN O O
i. NN O O
all NN O O
the NN O O
4003 NN O O
deltc NN O O
alleles NN O O
showed NN O O
the NN O O
same NN O O
haplotype NN O O
for NN O O
these NN O O
five NN O O

identification NN O B-MSH:D046349
of NN O I-MSH:D046349
a NN O O
novel NN O O
mutation NN O O

hereditary NN O B-MSH:D046349
coproporphyria NN O B-MSH:D030342
( NN O I-MSH:D030342
HCP NN B-SpecificDisease I-MSH:D030342
) NN O B-MSH:D046349
is NN O I-MSH:D046349
an NN O I-MSH:D046349
autosomal NN B-DiseaseClass B-MSH:D046349
dominant NN I-DiseaseClass O
disease NN I-DiseaseClass O
characterized NN O O
by NN O O
a NN O O
deficiency NN B-SpecificDisease O
of NN I-SpecificDisease O
coproporphyrinogen NN I-SpecificDisease O
oxidase NN I-SpecificDisease O
(cpo) NN O O
caused NN O O
by NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
cpo NN O O
gene. NN O O
only NN O O
11 NN O O
mutations NN O O
of NN O O
the NN O O
gene NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
HCP NN B-Modifier O
patients. NN O O
we NN O O
report NN O O
another NN O O
mutation NN O O
in NN O O
a NN O O
japanese NN O O
family. NN O O
polymerase NN O O
chain NN O O
reaction-single NN O O
strand NN O O
conformational NN O O
polymorphism NN O O
and NN O O
direct NN O O
sequence NN O O
analyses NN O O
demonstrated NN O O
a NN O O
c NN O O
to NN O O
t NN O O
substitution NN O O
in NN O O
exon NN O O
1 NN O O
of NN O O
the NN O O
cpo NN O O
gene NN O O
at NN O O
nucleotide NN O O
position NN O O
85, NN O O
which NN O O
lies NN O O
in NN O O
the NN O O
putative NN O O
presequence NN O O
for NN O O
targeting NN O O
to NN O O
mitochondria. NN O O
this NN O O
mutation NN O O
changes NN O O
the NN O O
codon NN O O
for NN O O
glutamine NN O O
to NN O O
a NN O O

), NN O O

the NN O B-OMIM:217000
chromosomal NN O I-OMIM:217000
order NN O I-OMIM:217000
of NN O I-OMIM:217000
genes NN O I-OMIM:217000
controlling NN O I-OMIM:217000
the NN O I-OMIM:217000
major NN O O
histocompatibility NN O O

the NN O B-OMIM:217000
relationship NN O I-OMIM:217000
of NN O I-OMIM:217000
the NN O I-OMIM:217000
genes NN O I-OMIM:217000
coding NN O I-OMIM:217000
for NN O I-OMIM:217000
hla NN O B-OMIM:217000
to NN O I-OMIM:217000
those NN O B-OMIM:217000
coding NN O I-OMIM:217000
for NN O B-OMIM:217000
properdin NN O I-OMIM:217000
factor NN O B-OMIM:217000
b NN O I-OMIM:217000
allotypes NN O O
and NN O O
for NN O O
deficiency NN B-SpecificDisease O
of NN I-SpecificDisease O
the NN I-SpecificDisease O
second NN I-SpecificDisease O
component NN I-SpecificDisease O
of NN I-SpecificDisease O
complement NN I-SpecificDisease O
(c NN O O
2) NN O O
was NN O O
studied NN O O
in NN O O
families NN O O
of NN O O
patients NN O O
with NN O O
connective NN O O
tissue NN O O
disorders. NN O O
patients NN O O
were NN O O
selected NN O O

allotype NN O B-OMIM:217000
and NN O I-OMIM:217000
hla-b NN O B-OMIM:217000
were NN O I-OMIM:217000
found. NN O B-OMIM:217000
of NN O I-OMIM:217000
72 NN O O
informative NN O O
meioses, NN O O
three NN O O

b NN O B-OMIM:217000
allotypes NN O I-OMIM:217000
are NN O O
approximately NN O O
3--5 NN O O
centimorgans NN O O
from NN O O
the NN O O
hla-a NN O O
and NN O O
hla-b NN O O
loci, NN O O
and NN O O
that NN O O
the NN O O
apparent NN O O
lack NN O O

a NN O B-MSH:D012175
novel NN O B-MSH:D009369
missense NN O O
mutation NN O O
in NN O O

we NN O B-MSH:D012175
have NN O B-MSH:D009369
used NN O I-MSH:D009369
single NN O B-MSH:D009369
strand NN O O
conformation NN O O
polymorphism NN O O
analysis NN O O
to NN O O
study NN O O
the NN O O
27 NN O O
exons NN O O
of NN O O
the NN O O
rb NN O O
1 NN O O
gene NN O O
in NN O O
individuals NN O O
from NN O O
a NN O O
family NN O O
showing NN O O
mild NN O O
expression NN O O
of NN O O
the NN O O

of NN O O

complement NN O O

seven NN O B-OMIM:610102
further NN O I-OMIM:610102
molecular NN O B-OMIM:610102
bases NN O I-OMIM:610102
of NN O O
C7 NN B-SpecificDisease O
deficiency NN I-SpecificDisease O

identification NN O B-MSH:C537346
of NN O I-MSH:C537346
constitutional NN O I-MSH:C537346
wt NN O O
1 NN O O
mutations, NN O O
in NN O O
patients NN O O
with NN O O
isolated NN O O
diffuse NN B-SpecificDisease O
mesangial NN I-SpecificDisease O
sclerosis NN I-SpecificDisease O
, NN O O
and NN O O
analysis NN O O

constitutional NN O B-MSH:D030321
mutations NN O I-MSH:D030321
of NN O B-MSH:D030321
the NN O B-MSH:C537346
wt NN O I-MSH:C537346
1 NN O I-MSH:C537346
gene, NN O B-MSH:C537346
encoding NN O B-MSH:D012734
a NN O B-MSH:D009396
zinc-finger NN O I-MSH:D009396
transcription NN O B-MSH:D009396
factor NN O B-MSH:D030321
involved NN O B-MSH:C537346
in NN O I-MSH:C537346
renal NN O B-MSH:C537346
and NN O B-MSH:D030321
gonadal NN O B-MSH:D014564
development, NN O I-MSH:D014564
are NN O B-MSH:D009396
found NN O B-MSH:C537346
in NN O O
most NN O O
patients NN O O

male NN O B-MSH:C537346
and NN O B-MSH:C537346
two NN O B-MSH:D030321
female NN O B-MSH:C537346
IDMS NN B-Modifier B-MSH:C537346
patients NN O O
with NN O O
wt NN O O
1 NN O O
mutations NN O O
underwent NN O O
normal NN O O
puberty. NN O O
two NN O O
mutations NN O O
associated NN O O
with NN O O
IDMS NN B-SpecificDisease O
are NN O O
different NN O O
from NN O O
those NN O O
described NN O O
in NN O O
DDS NN B-Modifier O
patients. NN O O

phenotype; NN O O

paternal NN O B-MSH:D009223
transmission NN O I-MSH:D009223
of NN O I-MSH:D009223
congenital NN B-SpecificDisease O

we NN O B-MSH:D009223
report NN O I-MSH:D009223
a NN O I-MSH:D009223
rare NN O B-MSH:D009223
case NN O B-MSH:D008607
of NN O I-MSH:D008607
paternally NN O B-MSH:D018908
transmitted NN O I-MSH:D018908
congenital NN B-SpecificDisease B-MSH:D009223
myotonic NN I-SpecificDisease B-MSH:D009223
dystrophy NN I-SpecificDisease I-MSH:D009223
( NN O I-MSH:D009223
DM NN B-SpecificDisease B-MSH:D009223
). NN O B-MSH:D009223
the NN O I-MSH:D009223
proband NN O O
is NN O O
a NN O O
23 NN O O
year NN O O
old, NN O O
mentally NN B-Modifier O
retarded NN I-Modifier O
male NN O O
who NN O O
suffers NN O O
severe NN O O
muscular NN B-DiseaseClass O
weakness NN I-DiseaseClass O

lengths NN O B-MSH:D009223
and NN O I-MSH:D009223
hence NN O B-MSH:D009223
less NN O I-MSH:D009223
severe NN O B-MSH:D009223
clinical NN O O
symptoms NN O O
than NN O O
the NN O O
mothers NN O O
of NN O O
children NN O O
with NN O O

genomic NN O O

the NN O B-MSH:D017204
ube NN O I-MSH:D017204
3 NN O B-MSH:D024182
a NN O I-MSH:D024182
gene NN O O
encodes NN O O
the NN O O
e NN O O
6-ap NN O O
ubiquitin-protein NN O O
ligase NN O O
and NN O O
has NN O O
recently NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
mutated NN O O
in NN O O
Angelman NN B-Modifier O
syndrome NN I-Modifier O
patients NN O O
who NN O O
lack NN O O
15 NN O O
q NN O O
11-q NN O O
13 NN O O
deletions NN O O
or NN O O
chromosome NN O O
15 NN O O
paternal NN O O
uniparental NN B-SpecificDisease O
disomy NN I-SpecificDisease O
. NN O O
previous NN O O
ube NN O O
3 NN O O
a NN O O
cdna NN O O
analysis NN O O
has NN O O
shown NN O O
a NN O O
coding NN O O
region NN O O
of NN O O
approximately NN O O
2. NN O O
6 NN O O
kb NN O O
and NN O O
a NN O O
3-untranslated NN O O
region NN O O
(utr) NN O O
of NN O O
< NN O O
50 NN O O
bp, NN O O
whereas NN O O
northern NN O O
analysis NN O O
has NN O O
indicated NN O O
mrna NN O O
sizes NN O O
of NN O O
5-8 NN O O
kb. NN O O
we NN O O
have NN O O
analyzed NN O O
additional NN O O
cdna NN O O
clones NN O O
and NN O O
provide NN O O
evidence NN O O
for NN O O

highly NN O O
homologous NN O O
processed NN O O
pseudogenes, NN O O
ube NN O O
3 NN O O
ap NN O O

distribution NN O B-MSH:D020389
of NN O I-MSH:D020389
emerin NN O I-MSH:D020389
and NN O O
lamins NN O O

emerin NN O B-MSH:D020389
is NN O I-MSH:D020389
a NN O I-MSH:D020389
nuclear NN O B-MSH:D020389
membrane NN O O
protein NN O O
which NN O O
is NN O O
missing NN O O
or NN O O
defective NN O O
in NN O O
Emery-Dreifuss NN B-SpecificDisease O
muscular NN I-SpecificDisease O
dystrophy NN I-SpecificDisease O
( NN O O
EDMD NN B-SpecificDisease O
). NN O O
it NN O O
is NN O O
one NN O O
member NN O O
of NN O O
a NN O O
family NN O O
of NN O O
lamina-associated NN O O
proteins NN O O
which NN O O
includes NN O O
lap NN O O
1, NN O O
lap NN O O
2 NN O O
and NN O O
lamin NN O O
b NN O O
receptor NN O O
(lbr). NN O O
a NN O O
panel NN O O
of NN O O
16 NN O O
monoclonal NN O O
antibodies NN O O
(mabs) NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
six NN O O
specific NN O O
sites NN O O
throughout NN O O
the NN O O
emerin NN O O
molecule NN O O
using NN O O
phage-displayed NN O O
peptide NN O O
libraries NN O O
and NN O O
has NN O O
been NN O O
used NN O O
to NN O O
localize NN O O
emerin NN O O
in NN O O
human NN O O
and NN O O
rabbit NN O O
heart. NN O O
several NN O O
mabs NN O O
against NN O O
different NN O O
emerin NN O O
epitopes NN O O
did NN O O
not NN O O
recognize NN O O
intercalated NN O O
discs NN O O
in NN O O
the NN O O
heart, NN O O
though NN O O
they NN O O
recognized NN O O
cardiomyocyte NN O O
nuclei NN O O
strongly, NN O O
both NN O O
at NN O O
the NN O O
rim NN O O
and NN O O
in NN O O
intranuclear NN O O
spots NN O O
or NN O O
channels. NN O O
a NN O O
polyclonal NN O O
rabbit NN O O
antiserum NN O O
against NN O O

a NN O B-MSH:D006330
pure-emerin NN O I-MSH:D006330
band NN O B-MSH:D020389
on NN O B-MSH:D020389
a NN O O
western NN O O
blot, NN O O
it NN O O
stained NN O O
only NN O O
the NN O O
nuclear NN O O
membrane. NN O O
these NN O O
results NN O O
would NN O O
not NN O O
be NN O O
expected NN O O
if NN O O
immunostaining NN O O
at NN O O
intercalated NN O O
discs NN O O
were NN O O
due NN O O
to NN O O
a NN O O
product NN O O
of NN O O
the NN O O
emerin NN O O
gene NN O O
and, NN O O
therefore, NN O O

is NN O B-MSH:D020389
also NN O O
almost NN O O
completely NN O O
absent NN O O
from NN O O
skeletal NN O O
muscle NN O O
nuclei. NN O O
in NN O O
EDMD NN B-SpecificDisease O
, NN O O
the NN O O
additional NN O O
absence NN O O
of NN O O
lamin NN O O
b NN O O
1 NN O O
from NN O O
heart NN O O
and NN O O
skeletal NN O O
muscle NN O O
nuclei NN O O
which NN O O
already NN O O
lack NN O O
emerin NN O O
may NN O O
offer NN O O

localization NN O B-MSH:D001943
of NN O I-MSH:D001943
human NN O I-MSH:D001943
brca NN O O
1 NN O O

although NN O B-MSH:D009369
the NN O B-MSH:D061325
link NN O I-MSH:D061325
between NN O I-MSH:D061325
the NN O I-MSH:D061325
brca NN O I-MSH:D061325
1 NN O B-MSH:D009369
tumour NN B-Modifier B-MSH:D009369
-suppressor NN O I-MSH:D009369
gene NN O B-MSH:D001943
and NN O I-MSH:D001943
hereditary NN B-CompositeMention I-MSH:D001943
breast NN I-CompositeMention I-MSH:D001943
and NN I-CompositeMention O
ovarian NN I-CompositeMention O
cancer NN I-CompositeMention O
is NN O O
established, NN O O
the NN O O
role, NN O O
if NN O O
any, NN O O
of NN O O
brca NN O O
1 NN O O
in NN O O
non-familial NN B-DiseaseClass O
cancers NN I-DiseaseClass O
is NN O O
unclear. NN O O
brca NN O O
1 NN O O
mutations NN O O
are NN O O
rare NN O O
in NN O O
sporadic NN B-DiseaseClass O
cancers NN I-DiseaseClass O
, NN O O
but NN O O
loss NN O O
of NN O O
brca NN O O
1 NN O O
resulting NN O O
from NN O O
reduced NN O O
expression NN O O
or NN O O
incorrect NN O O
subcellular NN O O
localization NN O O
is NN O O
postulated NN O O
to NN O O
be NN O O
important NN O O
in NN O O
non-familial NN B-CompositeMention O
breast NN I-CompositeMention O
and NN I-CompositeMention O
ovarian NN I-CompositeMention O
cancers NN I-CompositeMention O
. NN O O

these NN O B-MSH:D001943
reagents NN O I-MSH:D001943
detect NN O B-MSH:D018275
a NN O I-MSH:D018275
220-kd NN O I-MSH:D018275
protein NN O B-MSH:D044584
localized NN O I-MSH:D044584
in NN O I-MSH:D044584
discrete NN O B-MSH:D044584
nuclear NN O I-MSH:D044584
foci NN O B-MSH:D001943
in NN O I-MSH:D001943
all NN O I-MSH:D001943
epithelial NN O O
cell NN O O

